1
|
Efimov A, Dagallier C, Frochot C, Myrzakhmetov B, Arnoux P, Heinonen T, Mannerström M, Toimela T, Ahmed Z, Audibert JF, Habermeyer B, Mordon S, Pansu RB. LASU: An efficient and stable phthalocyanine dye with tolerable safety profile for self-disinfecting anti-COVID textiles activated by ambient light. Photodiagnosis Photodyn Ther 2024; 45:103978. [PMID: 38237650 DOI: 10.1016/j.pdpdt.2024.103978] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2023] [Revised: 01/15/2024] [Accepted: 01/16/2024] [Indexed: 01/27/2024]
Abstract
BACKGROUND Recent COVID crisis has demonstrated that modern society urgently needs an accessible protection against mass infections, especially viruses, as the new strains are appearing at an ever-increasing pace and cause severe harm to the population and the world economy. METHODS We have developed an efficient phthalocyanine photosensitizer LASU, that is suitable for dyeing textiles and allows to prepare reusable self-disinfecting fabrics with strong antiviral properties. The safety profile of LASU was evaluated in accredited laboratories by several in vitro assays according to the OECD-guidelines. RESULTS The textiles impregnated with LASU phthalocyanine showed a significant antiviral photodynamic effect even under moderate indoor and outdoor light. The dye did not show any genotoxic potential in human lymphocyte micronucleus assay. It showed a possible indication for eye irritation in human EpiOcular™ model and was phototoxic when tested in mouse BALB/c 3T3 cell test in the presence and absence of UVA-irradiation. CONCLUSION Novel phthalocyanine-dyed textiles are suitable for general use as self-disinfecting antiviral barriers and materials in hospitals, households, and public places. The safety profile of LASU is the phototoxic effect which is related to LASU´s mode of action.
Collapse
Affiliation(s)
| | | | - Céline Frochot
- Université de Lorraine, CNRS, LRGP, F-54000 Nancy, France
| | | | | | | | | | | | | | - Jean Frédéric Audibert
- LuMIn UMR9024 du CNRS, ENS Paris-Saclay, Université Paris-Saclay, CentraleSupélec, Gif sur Yvette, France
| | | | - Serge Mordon
- Hemerion Therapeutics, Villeneuve d'Ascq, France
| | - Robert Bernard Pansu
- LuMIn UMR9024 du CNRS, ENS Paris-Saclay, Université Paris-Saclay, CentraleSupélec, Gif sur Yvette, France
| |
Collapse
|
2
|
Haykal D, Cartier H, Maire C, Mordon S. Picosecond lasers in cosmetic dermatology: where are we now? An overview of types and indications. Lasers Med Sci 2023; 39:8. [PMID: 38110831 DOI: 10.1007/s10103-023-03945-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2023] [Accepted: 12/05/2023] [Indexed: 12/20/2023]
Abstract
Q-switched lasers have undeniably revolutionized the field of laser dermatology since four decades ago. Just as the first-generation laser emits its photonic signal in a few nanoseconds, the picosecond laser delivers pulse widths of at least ten times shorter. These devices offer a powerful tool for treating a wide range of skin conditions with a minimal downtime for visible improvement. For the current study, a literature research was performed on the dermatological applications of picosecond laser. The literature searched on this topic between 1999 and 2023 accessible through various platforms produce a result of 62 articles. The included studies have discussed the application of picosecond laser technology in tattoo removal, treatment of epidermal and dermal pigmentation, and collagen remodeling. After sifting the data from the articles into tables, the results were discussed in detail. The study shows a lot of evidence towards the efficacy of picosecond laser, yet it draws attention to its downsides.
Collapse
Affiliation(s)
- Diala Haykal
- Centre Laser Palaiseau, 49 Ter Rue de Paris, 91120, Palaiseau, France.
| | | | | | - Serge Mordon
- Hemerion Therapeutics, Villeneuve d'Ascq, France
| |
Collapse
|
3
|
Creusot M, Mordon S. Clinical evaluation of a short illumination duration (1 hour) when performing photodynamic therapy of actinic keratosis using the Dermaris light source. Photodiagnosis Photodyn Ther 2021; 36:102618. [PMID: 34743007 DOI: 10.1016/j.pdpdt.2021.102618] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2021] [Revised: 10/30/2021] [Accepted: 11/01/2021] [Indexed: 11/18/2022]
Abstract
BACKGROUND Photodynamic therapy (PDT) using daylight as the photoactivating light source (DL-PDT) is an effective treatment for actinic keratosis (AK). Among the artificial daylight sources, the Dermaris (Surgiris, Croix, France) is specially designed for SDL-PDT (simulated daylight PDT) of AK. To perform the PDT session, a long duration (2.5 h) and low-intensity light exposure (2.9 mw/cm²) is used. This long duration is considered as a major limitation by both the patient and the dermatologist. OBJECTIVES The paper aims to report the clinical outcomes of SDL-PDT using the Dermaris in patients treated for AK lesions of the scalp at our medical dermatology center using only one hour low-intensity light exposure. METHODS Thirty patients (19 males, 11 females), mean age: 72.8 ± 9.3, with phototype 1 (11 patients), with phototype 2(17 patients) and phototype 3 (2 patients), with grade I-II AK of the scalp were treated with a drug-light interval (DLI) of 10 min and a light exposure of 1 h. The cure rate of AK lesions at six months after the treatment was determined. Erythema, crusts, discomfort and during or/and post the treatment were also evaluated. RESULTS In total, 293 AK were treated. Six months following treatment, the cure rate of patients was 93%. Pain score reported after the first PDT session was from 0 to 1 on a visual analogue scale (VAS) ranging from 0 to 10. Erythema was observed in 28 patients and lasted 3 days, crusts were seen in 19 patients. Discomfort was as mild or less in more than 97% of patients. CONCLUSIONS the shortening of the exposure time to one hour does not modify the efficacy of the SDL-PDT using the Dermaris. This observation is in agreement with recent published data demonstrating that PDT can be performed successfully with half the illumination time used in daylight PDT today. Besides, this clinical study confirmed that SDL-PDT is an effective and nearly painless treatment with minimal side effects for patients with AK lesions of the scalp.
Collapse
Affiliation(s)
- M Creusot
- Centre Dermatologique du Roy, Lasne - Plancenoit, Belgium
| | - S Mordon
- Inserm U1026, University Bordeaux Segalen, Bordeaux, France.
| |
Collapse
|
4
|
Le Calvé C, Abi-Rached H, Vicentini C, Maire C, Delaporte E, Mordon S, Staumont-Sallé D, Mortier L. Treatment of folliculitis decalvans by photodynamic therapy using a new light-emitting device: A case series of 4 patients. JAAD Case Rep 2021; 17:69-72. [PMID: 34703869 PMCID: PMC8524730 DOI: 10.1016/j.jdcr.2021.09.026] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Affiliation(s)
- Claire Le Calvé
- Department of Dermatology, Lille University, Centre Hospitalo-Universitaire Lille, Lille, France
| | - Henry Abi-Rached
- Department of Dermatology, Lille University, Centre Hospitalo-Universitaire Lille, Lille, France
| | - Claire Vicentini
- Department of Dermatology, Lille University, Centre Hospitalo-Universitaire Lille, Lille, France
| | - Cyril Maire
- Department of Dermatology, Centre Hospitalo-Universitaire Lille, Institut National de la Sante Et de la Recherche Médicale U1189, Lille, France
| | - Emmanuel Delaporte
- Department of Dermatology, Aix-Marseille University, University Hospital Center of Marseille (Hôpital Nord), Marseille, France
| | - Serge Mordon
- Bordeaux Segalen University, Institut National de la Sante Et de la Recherche Médicale U1026, Bordeaux, France
| | - Delphine Staumont-Sallé
- Lille University, Institut National de la Sante Et de la Recherche Médicale U1286 Institute for Translational Research in Inflammation, Centre Hospitalo-Universitaire Lille, Lille, France
| | - Laurent Mortier
- Department of Dermatology, University of Lille, Institut National de la Sante Et de la Recherche Médicale U1189, Centre Hospitalo-Universitaire Lille, Lille, France
| |
Collapse
|
5
|
Leroy HA, Guérin L, Lecomte F, Baert G, Vignion AS, Mordon S, Reyns N. Is interstitial photodynamic therapy for brain tumors ready for clinical practice? A systematic review. Photodiagnosis Photodyn Ther 2021; 36:102492. [PMID: 34419674 DOI: 10.1016/j.pdpdt.2021.102492] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2021] [Revised: 08/06/2021] [Accepted: 08/17/2021] [Indexed: 12/29/2022]
Abstract
BACKGROUND Interstitial photodynamic therapy (iPDT), inserting optical fibers inside brain tumors, has been proposed for more than 30 years. While a promising therapeutic option, it is still an experimental treatment, with different ways of application, depending on the team performing the technique. OBJECTIVE In this systematic review, we reported the patient selection process, the treatment parameters, the potential adverse events and the oncological outcomes related to iPDT treatment applied to brain tumors. METHODS We performed a search in PubMed, Embase and Medline based on the following Mesh terms: "interstitial" AND "photodynamic therapy" AND "brain tumor" OR "glioma" OR glioblastoma" from January 1990 to April 2020. We screened 350 studies. Twelve matched all selection criteria. RESULTS 251 patients underwent iPDT. Tumors were mainly de novo or recurrent high-grade gliomas (171 (68%) of glioblastomas), located supratentorial, with a median volume of 12 cm3. Hematoporphyrin derive agent (HpD) or protoporphyrin IX (PpIX) induced by 5-aminolevulinic acid (5-ALA) was used as a photosensitizer. Up to 6 optical fibers were introduced inside the tumor, delivering 200 mW/cm at a wavelength of 630 nm. Overall mortality was 1%. Transient and persistent morbidity were both 5%. No permanent deficit occurred using 5-ALA PDT. Tumor response rate after iPDT was 92% (IQR, 67; 99). Regarding glioblastomas, progression-free-survival was respectively 14.5 months (IQR, 13.8; 15.3) for de novo lesions and 14 months (IQR, 7; 30) for recurrent lesions, while overall survival was respectively 19 months (IQR, 14; 20) and 8 months (IQR, 6.3; 8.5). In patients harboring high-grade gliomas, 33 (13%) were considered long-term survivors (> 2 years) after iPDT. CONCLUSION Regardless of heterogeneity in its application, iPDT appears safe and efficient to treat brain tumors, especially high-grade gliomas. Stand-alone iPDT (i.e., without combined craniotomy and intracavitary PDT) using 5-ALA appears to be the best option in terms of controlling side effects: it avoids the occurrence of permanent neurological deficits while reducing the risks of hemorrhage and sepsis.
Collapse
Affiliation(s)
- Henri-Arthur Leroy
- CHU Lille, Department of Neurosurgery, F-59000 Lille, France; INSERM, CHU-Lille, U1189-ONCOTHAI-Assisted Laser Therapy and Immunotherapy for Oncology, Univ-Lille, F-59000 Lille, France.
| | - Laura Guérin
- INSERM, CHU-Lille, U1189-ONCOTHAI-Assisted Laser Therapy and Immunotherapy for Oncology, Univ-Lille, F-59000 Lille, France
| | - Fabienne Lecomte
- INSERM, CHU-Lille, U1189-ONCOTHAI-Assisted Laser Therapy and Immunotherapy for Oncology, Univ-Lille, F-59000 Lille, France
| | - Grégory Baert
- INSERM, CHU-Lille, U1189-ONCOTHAI-Assisted Laser Therapy and Immunotherapy for Oncology, Univ-Lille, F-59000 Lille, France
| | - Anne-Sophie Vignion
- INSERM, CHU-Lille, U1189-ONCOTHAI-Assisted Laser Therapy and Immunotherapy for Oncology, Univ-Lille, F-59000 Lille, France
| | - Serge Mordon
- INSERM, CHU-Lille, U1189-ONCOTHAI-Assisted Laser Therapy and Immunotherapy for Oncology, Univ-Lille, F-59000 Lille, France
| | - Nicolas Reyns
- CHU Lille, Department of Neurosurgery, F-59000 Lille, France; INSERM, CHU-Lille, U1189-ONCOTHAI-Assisted Laser Therapy and Immunotherapy for Oncology, Univ-Lille, F-59000 Lille, France
| |
Collapse
|
6
|
Lecomte F, Thecua E, Ziane L, Deleporte P, Duhamel A, Vamour C, Mordon S, Rakza T. Phototherapy Using a Light-Emitting Fabric (BUBOLight) Device in the Treatment of Newborn Jaundice: Protocol for an Interventional Feasibility and Safety Study. JMIR Res Protoc 2021; 10:e24808. [PMID: 34032584 PMCID: PMC8188309 DOI: 10.2196/24808] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2020] [Revised: 01/04/2021] [Accepted: 01/06/2021] [Indexed: 11/13/2022] Open
Abstract
Background Neonatal jaundice is a common condition occurring in 60%-80% of all healthy-term and late-preterm neonates. In the majority of cases, neonatal jaundice resolves spontaneously and causes no harm; however, in some neonates, significant hyperbilirubinemia can develop and lead to kernicterus jaundice, a serious neurological disease. Phototherapy (PT) is the preferred treatment for jaundice; however, to be effective, PT devices need to have a broad light emission surface to generate no or little heat and to provide an optimal wavelength and light intensity (420-490 nm and ≥30 µW/cm²/nm, respectively). Objective This study aimed to investigate the feasibility, safety, and level of satisfaction of parents and health care teams with the BUBOlight device, an innovative alternative to conventional hospital PT, in which luminous textiles have been incorporated in a sleeping bag. Methods This interventional, exploratory, simple group, nonrandomized, single-center trial will be conducted at Lille Hospital. In total, 10-15 neonates and their parents will be included to obtain evaluable data from 10 parent-neonate pairs. Neonates weighing more than 2500 g at birth and born with ≥37 weeks of amenorrhea that required PT in accordance with the guidelines of the National Institute For Health and Clinical Excellence will receive one 4-hour session of illumination. Total serum bilirubin and transcutaneous bilirubin levels were obtained at the start and 2 hours after the end of PT. Cutaneous and rectal temperatures, heart rate, and oxygen saturation will be measured at the beginning and during PT. The number of subjects is therefore not calculated on the basis of statistical assumptions. We aim to obtain a minimum proportion of 90% (ie, 9 of 10) of the neonates included, who have been able to undergo 4-hour PT without unacceptable and unexpected toxicities. We will calculate the mean, median, quartiles, minimum and maximum values of the quantitative parameters, and the frequency of the qualitative parameters. The rate of patients with no unacceptable and unexpected toxicities (ie, the primary endpoint) will be calculated. Results The first patient is expected to be enrolled at the end of 2020, and clinical investigations are intended for up to June 2021. The final results of this study are expected to be available at the end of 2021. Conclusions Our findings will provide insights into the safety and feasibility of a new PT device based on light-emitting fabrics for the treatment of newborn jaundice. This new system, if proven effective, will improve the humanization of neonatal care and help avoid mother-child separation. Trial Registration ClinicalTrials.gov NCT04365998; https://clinicaltrials.gov/ct2/show/NCT04365998 International Registered Report Identifier (IRRID) PRR1-10.2196/24808
Collapse
Affiliation(s)
- Fabienne Lecomte
- U1189 - Assisted Laser Therapy and Immunotherapy for Oncology, Univ- Lille, Inserm, CHU Lille, F-59000 Lille, France
| | - Elise Thecua
- U1189 - Assisted Laser Therapy and Immunotherapy for Oncology, Univ- Lille, Inserm, CHU Lille, F-59000 Lille, France
| | - Laurine Ziane
- U1189 - Assisted Laser Therapy and Immunotherapy for Oncology, Univ- Lille, Inserm, CHU Lille, F-59000 Lille, France
| | - Pascal Deleporte
- U1189 - Assisted Laser Therapy and Immunotherapy for Oncology, Univ- Lille, Inserm, CHU Lille, F-59000 Lille, France
| | - Alain Duhamel
- EA 2694 - Santé publique: épidémiologie et qualité des soins, Univ- Lille, CHU Lille, F-59000 Lille, France
| | - Clémence Vamour
- Jeanne de Flandre Hospital, Department of Obstetrics, CHU Lille, F-59000 Lille, France
| | - Serge Mordon
- U1189 - Assisted Laser Therapy and Immunotherapy for Oncology, Univ- Lille, Inserm, CHU Lille, F-59000 Lille, France
| | - Thameur Rakza
- EA4489, Perinatal Growth and Health, Jeanne de Flandre Hospital, Department of Obstetrics, Univ- Lille, CHU Lille, F-59000 Lille, France
| |
Collapse
|
7
|
Vermandel M, Dupont C, Lecomte F, Leroy HA, Tuleasca C, Mordon S, Hadjipanayis CG, Reyns N. Standardized intraoperative 5-ALA photodynamic therapy for newly diagnosed glioblastoma patients: a preliminary analysis of the INDYGO clinical trial. J Neurooncol 2021; 152:501-514. [PMID: 33743128 DOI: 10.1007/s11060-021-03718-6] [Citation(s) in RCA: 34] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2020] [Accepted: 02/13/2021] [Indexed: 12/11/2022]
Abstract
PURPOSE Glioblastoma (GBM) is the most aggressive malignant primary brain tumor. The unfavorable prognosis despite maximal therapy relates to high propensity for recurrence. Thus, overall survival (OS) is quite limited and local failure remains the fundamental problem. Here, we present a safety and feasibility trial after treating GBM intraoperatively by photodynamic therapy (PDT) after 5-aminolevulinic acid (5-ALA) administration and maximal resection. METHODS Ten patients with newly diagnosed GBM were enrolled and treated between May 2017 and June 2018. The standardized therapeutic approach included maximal resection (near total or gross total tumor resection (GTR)) guided by 5-ALA fluorescence-guided surgery (FGS), followed by intraoperative PDT. Postoperatively, patients underwent adjuvant therapy (Stupp protocol). Follow-up included clinical examinations and brain MR imaging was performed every 3 months until tumor progression and/or death. RESULTS There were no unacceptable or unexpected toxicities or serious adverse effects. At the time of the interim analysis, the actuarial 12-months progression-free survival (PFS) rate was 60% (median 17.1 months), and the actuarial 12-months OS rate was 80% (median 23.1 months). CONCLUSIONS This trial assessed the feasibility and the safety of intraoperative 5-ALA PDT as a novel approach for treating GBM after maximal tumor resection. The current standard of care remains microsurgical resection whenever feasible, followed by adjuvant therapy (Stupp protocol). We postulate that PDT delivered immediately after resection as an add-on therapy of this primary brain cancer is safe and may help to decrease the recurrence risk by targeting residual tumor cells in the resection cavity. Trial registration NCT number: NCT03048240. EudraCT number: 2016-002706-39.
Collapse
Affiliation(s)
- Maximilien Vermandel
- Univ. Lille, Inserm, CHU Lille, U1189 - ONCO-THAI -Laser Assisted Therapies and Immunotherapies for Oncology, 59000, Lille, France
- Neurosurgery Department, CHU Lille, 59000, Lille, France
| | - Clément Dupont
- Univ. Lille, Inserm, CHU Lille, U1189 - ONCO-THAI -Laser Assisted Therapies and Immunotherapies for Oncology, 59000, Lille, France
| | - Fabienne Lecomte
- Univ. Lille, Inserm, CHU Lille, U1189 - ONCO-THAI -Laser Assisted Therapies and Immunotherapies for Oncology, 59000, Lille, France
| | - Henri-Arthur Leroy
- Univ. Lille, Inserm, CHU Lille, U1189 - ONCO-THAI -Laser Assisted Therapies and Immunotherapies for Oncology, 59000, Lille, France
- Neurosurgery Department, CHU Lille, 59000, Lille, France
| | - Constantin Tuleasca
- Faculty of Biology and Medicine (FBM) and Centre Hospitalier Universitaire Vaudois (CHUV), Clinical Neurosciences Department, Neurosurgery Service and Gamma Knife Center, University of Lausanne (Unil), Lausanne, Switzerland
- Signal Processing Laboratory (LTS 5), Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | - Serge Mordon
- Univ. Lille, Inserm, CHU Lille, U1189 - ONCO-THAI -Laser Assisted Therapies and Immunotherapies for Oncology, 59000, Lille, France
| | - Constantinos G Hadjipanayis
- Department of Neurosurgery, Icahn School of Medicine At Mount Sinai, Mount Sinai Health System, New York, NY, USA
- Department of Neurosurgery, Mount Sinai Beth Israel, New York, NY, USA
| | - Nicolas Reyns
- Univ. Lille, Inserm, CHU Lille, U1189 - ONCO-THAI -Laser Assisted Therapies and Immunotherapies for Oncology, 59000, Lille, France.
- Neurosurgery Department, CHU Lille, 59000, Lille, France.
| |
Collapse
|
8
|
Kerbage Y, Rouillès J, Vignion AS, Delhem N, Thecua E, Deleporte P, Collinet P, Mordon S. Laser interstitial thermotherapy (LITT) for breast cancer: dosimetry optimization and numerical simulation. Lasers Med Sci 2021; 37:489-498. [PMID: 33713256 DOI: 10.1007/s10103-021-03286-1] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2021] [Accepted: 03/02/2021] [Indexed: 10/21/2022]
Abstract
Surgical treatment is standard for the treatment of small breast cancers. Due to the pain and esthetic sequelae that can follow surgery, minimally invasive treatments are under investigation. Our aim was to conduct a dosimetry study of laser interstitial thermotherapy. Turkey tissue was used as an ex vivo model, and mammary glands from ewes were used as in vivo models. We used two different wavelength lasers (805 nm and 980 nm). Two types of fiber from two different manufacturers were used: bare fibers with a diameter of 600 μm and diffusing fiber. The diffusing fibers were 5 mm and 10 mm in length. We also used a computerized model to predict thermal damage and to correlate with the ex vivo and in vivo procedures using a constant and variable coefficient. The mathematical model was based on the finite element method for solving light distribution, bio-heat, and thermal damage equations. Based on our ex vivo and in vivo experiments, we found that the optimal configuration for this treatment was the use of the 980-nm laser at 4 W with bare fibers for a minimum treatment time of 150 s. We also developed a predictive mathematical model that showed good predictability of necrosis in line with the experimental data. Laser treatment is a promising therapy for small breast lesions. However, further development of treatment guidance is necessary to support its use in clinical practice.
Collapse
Affiliation(s)
- Yohan Kerbage
- Univ. Lille, CHU Lille, U 1189, ONCO-THAI- Image Assisted Laser Therapy for Oncology, 1 avenue Oscar Lambret, F-59000, Lille, France. .,CHU Lille, Service de chirurgie gynécologique, F-59000, Lille, France.
| | - Julie Rouillès
- CHU Lille, Service de chirurgie gynécologique, F-59000, Lille, France
| | - Anne-Sophie Vignion
- Univ. Lille, CHU Lille, U 1189, ONCO-THAI- Image Assisted Laser Therapy for Oncology, 1 avenue Oscar Lambret, F-59000, Lille, France
| | - Nadira Delhem
- Univ. Lille, CHU Lille, U 1189, ONCO-THAI- Image Assisted Laser Therapy for Oncology, 1 avenue Oscar Lambret, F-59000, Lille, France.,CNRS, UMR8161, Institut de Biologie de Lille, Univ. Lille, Institut Pasteur de Lille, Lille, France
| | - Elise Thecua
- Univ. Lille, CHU Lille, U 1189, ONCO-THAI- Image Assisted Laser Therapy for Oncology, 1 avenue Oscar Lambret, F-59000, Lille, France
| | - Pascal Deleporte
- Univ. Lille, CHU Lille, U 1189, ONCO-THAI- Image Assisted Laser Therapy for Oncology, 1 avenue Oscar Lambret, F-59000, Lille, France
| | - Pierre Collinet
- Univ. Lille, CHU Lille, U 1189, ONCO-THAI- Image Assisted Laser Therapy for Oncology, 1 avenue Oscar Lambret, F-59000, Lille, France.,CHU Lille, Service de chirurgie gynécologique, F-59000, Lille, France
| | - Serge Mordon
- Univ. Lille, CHU Lille, U 1189, ONCO-THAI- Image Assisted Laser Therapy for Oncology, 1 avenue Oscar Lambret, F-59000, Lille, France
| |
Collapse
|
9
|
Julienne A, Donatini G, Richer JP, Brèque C, Mordon S, Faure JP, Danion J, Bertheuil N, Leclère FM. [Flap harvest training on a new ultrarealistic simulation model: In-training operator feedback about a pulsating reperfused and reventilated cadaver Simlife®]. ANN CHIR PLAST ESTH 2021; 66:126-133. [PMID: 33707027 DOI: 10.1016/j.anplas.2020.12.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2020] [Revised: 12/07/2020] [Accepted: 12/09/2020] [Indexed: 10/22/2022]
Abstract
INTRODUCTION The anatomical subject is still a key element to learn complex procedures in plastic surgery. We present here the evaluation of an in-training operator on a SIMLIFE® model, hyper realistic model consisting in human bodies donated to science equipped with pulsating recirculation and reventilation device. MATERIAL AND METHODS From February 2019 to October 2019, 8 forearm flaps with radial proximal pedicle were harvested by the learner on a SIMLIFE® model. Conditions were as close as possible to the operating room : asepsy, sterile draping, assistant and instrumentation including electrocoagulation. RESULTS The procedure was decomposed in 13 distinct steps. Mean total surgery time was 90,5±11,62minutes. There was only one case of arterial pedicle lesion resulting in major blood leak. Bleeding was measured by fake blood loss from the SIMLIFE® console. Mean intraoperatoy bleeding was 171±108 milliliters. We review pros and cons of this new technology particulary suited for complex plastic and reconstructive surgery training. CONCLUSION Using SIMLIFE® technology we have a new mean to train for complex procedures in plastic and reconstructive surgery. This new technology could be applied to numerous other surgical procedures. Broader applications are still limited by cost and cadaver use legislation.
Collapse
Affiliation(s)
- A Julienne
- Laboratoire d'anatomie et de simulation de l'université de Poitiers, ABS Lab-Bât D1, 6, rue de la Miletrie TSA-51115, 86073 Poitiers cedex 9, France; Department of Plastic & Reconstructive Surgery, Hand Surgery, Centre of Expertise for Sex Reassignment Surgery, University Hospital Poitiers, CHU de la Miletrie de Poitiers, 2, rue de la Milétrie, 86000 Poitiers, France.
| | - G Donatini
- Laboratoire d'anatomie et de simulation de l'université de Poitiers, ABS Lab-Bât D1, 6, rue de la Miletrie TSA-51115, 86073 Poitiers cedex 9, France; Department of General Surgery, University Hospital Poitiers, CHU de la Miletrie de Poitiers, 2, rue de la Milétrie, 86000 Poitiers, France
| | - J P Richer
- Laboratoire d'anatomie et de simulation de l'université de Poitiers, ABS Lab-Bât D1, 6, rue de la Miletrie TSA-51115, 86073 Poitiers cedex 9, France; Department of General Surgery, University Hospital Poitiers, CHU de la Miletrie de Poitiers, 2, rue de la Milétrie, 86000 Poitiers, France
| | - C Brèque
- Laboratoire d'anatomie et de simulation de l'université de Poitiers, ABS Lab-Bât D1, 6, rue de la Miletrie TSA-51115, 86073 Poitiers cedex 9, France
| | - S Mordon
- Inserm U1189-ONCO-THAI-Image Assisted Laser Therapy for Oncology, University Hospital Lille, Lille, France
| | - J P Faure
- Laboratoire d'anatomie et de simulation de l'université de Poitiers, ABS Lab-Bât D1, 6, rue de la Miletrie TSA-51115, 86073 Poitiers cedex 9, France; Department of General Surgery, University Hospital Poitiers, CHU de la Miletrie de Poitiers, 2, rue de la Milétrie, 86000 Poitiers, France
| | - J Danion
- Laboratoire d'anatomie et de simulation de l'université de Poitiers, ABS Lab-Bât D1, 6, rue de la Miletrie TSA-51115, 86073 Poitiers cedex 9, France; Department of General Surgery, University Hospital Poitiers, CHU de la Miletrie de Poitiers, 2, rue de la Milétrie, 86000 Poitiers, France
| | - N Bertheuil
- Department of plastic, reconstructive and aesthetic surgery, hospital Sud, university of Rennes 1, Rennes, France
| | - F M Leclère
- Laboratoire d'anatomie et de simulation de l'université de Poitiers, ABS Lab-Bât D1, 6, rue de la Miletrie TSA-51115, 86073 Poitiers cedex 9, France; Department of Plastic & Reconstructive Surgery, Hand Surgery, Centre of Expertise for Sex Reassignment Surgery, University Hospital Poitiers, CHU de la Miletrie de Poitiers, 2, rue de la Milétrie, 86000 Poitiers, France; Inserm U1189-ONCO-THAI-Image Assisted Laser Therapy for Oncology, University Hospital Lille, Lille, France
| |
Collapse
|
10
|
Myrzakhmetov B, Arnoux P, Mordon S, Acherar S, Tsoy I, Frochot C. Photophysical Properties of Protoporphyrin IX, Pyropheophorbide-a and Photofrin ® in Different Conditions. Pharmaceuticals (Basel) 2021; 14:ph14020138. [PMID: 33572282 PMCID: PMC7914864 DOI: 10.3390/ph14020138] [Citation(s) in RCA: 33] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2021] [Accepted: 02/07/2021] [Indexed: 12/11/2022] Open
Abstract
Photodynamic therapy (PDT) is an innovative treatment of malignant or diseased tissues. The effectiveness of PDT depends on light dosimetry, oxygen availability, and properties of the photosensitizer (PS). Depending on the medium, photophysical properties of the PS can change leading to increase or decrease in fluorescence emission and formation of reactive oxygen species (ROS) especially singlet oxygen (1O2). In this study, the influence of solvent polarity, viscosity, concentration, temperature, and pH medium on the photophysical properties of protoporphyrin IX, pyropheophorbide-a, and Photofrin® were investigated by UV-visible absorption, fluorescence emission, singlet oxygen emission, and time-resolved fluorescence spectroscopies.
Collapse
Affiliation(s)
- Bauyrzhan Myrzakhmetov
- LRGP UMR 7274, CNRS, University of Lorraine, 54000 Nancy, France; (B.M.); (P.A.)
- Department of Chemistry and Chemical Technology, M.Kh. Dulaty Taraz Regional University, Taraz 080012, Kazakhstan;
| | - Philippe Arnoux
- LRGP UMR 7274, CNRS, University of Lorraine, 54000 Nancy, France; (B.M.); (P.A.)
| | - Serge Mordon
- ONCO-THAI U1189, INSERM, CHU Lille, University of Lille, 59000 Lille, France;
| | - Samir Acherar
- LCPM UMR 7375, CNRS, University of Lorraine, 54000 Nancy, France;
| | - Irina Tsoy
- Department of Chemistry and Chemical Technology, M.Kh. Dulaty Taraz Regional University, Taraz 080012, Kazakhstan;
| | - Céline Frochot
- LRGP UMR 7274, CNRS, University of Lorraine, 54000 Nancy, France; (B.M.); (P.A.)
- Correspondence: ; Tel.: +33-372743780
| |
Collapse
|
11
|
Azaïs H, Vignion-Dewalle AS, Carrier M, Augustin J, Da Maïa E, Penel A, Belghiti J, Nikpayam M, Gonthier C, Ziane L, Mordon S, Collinet P, Canlorbe G, Uzan C. Microscopic Peritoneal Residual Disease after Complete Macroscopic Cytoreductive Surgery for Advanced High Grade Serous Ovarian Cancer. J Clin Med 2020; 10:E41. [PMID: 33375564 PMCID: PMC7795826 DOI: 10.3390/jcm10010041] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2020] [Revised: 12/23/2020] [Accepted: 12/23/2020] [Indexed: 01/13/2023] Open
Abstract
BACKGROUND Epithelial ovarian cancers (EOC) are usually diagnosed at an advanced stage and managed by complete macroscopic cytoreductive surgery (CRS) and systemic chemotherapy. Peritoneal recurrence occurs in 60% of patients and may be due to microscopic peritoneal metastases (mPM) which are neither eradicated by surgery nor controlled by systemic chemotherapy. The aim of this study was to assess and quantify the prevalence of residual mPM after complete macroscopic CRS in patients with advanced high-grade serous ovarian cancer (HGSOC). METHODS A prospective study conducted between 1 June 2018 and 10 July 2019 in a single referent center accredited by the European Society of Gynecological Oncology for advanced EOC management. Consecutive patients presenting with advanced HGSOC and eligible for complete macroscopic CRS were included. Up to 13 peritoneal biopsies were taken from macroscopically healthy peritoneum at the end of CRS and examined for the presence of mPM. A mathematical model was designed to determine the probability of presenting at least one mPM after CRS. RESULTS 26 patients were included and 26.9% presented mPM. There were no differences in characteristics between patients with or without identified mPM. After mathematical analysis, the probability that mPM remained after complete macroscopic CRS in patients with EOC was 98.14%. CONCLUSION Microscopic PM is systematically present after complete macroscopic CRS for EOC and could be a relevant therapeutic target. Adjuvant locoregional strategies to conventional surgery may improve survival by achieving microscopic CRS.
Collapse
Affiliation(s)
- Henri Azaïs
- Department of Gynecological and Breast Surgery and Oncology, Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié-Salpêtrière University Hospital, 75013 Paris, France; (M.C.); (J.B.); (M.N.); (C.G.); (G.C.); (C.U.)
- U1189-ONCO-THAI-Laser Assisted Therapy and Immunotherapies for On-cology, CHU Lille, Université de Lille, INSERM, F-59000 Lille, France; (A.-S.V.-D.); (L.Z.); (S.M.); (P.C.)
| | - Anne-Sophie Vignion-Dewalle
- U1189-ONCO-THAI-Laser Assisted Therapy and Immunotherapies for On-cology, CHU Lille, Université de Lille, INSERM, F-59000 Lille, France; (A.-S.V.-D.); (L.Z.); (S.M.); (P.C.)
| | - Marine Carrier
- Department of Gynecological and Breast Surgery and Oncology, Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié-Salpêtrière University Hospital, 75013 Paris, France; (M.C.); (J.B.); (M.N.); (C.G.); (G.C.); (C.U.)
| | - Jeremy Augustin
- AP-HP, Pitié-Salpêtrière Hospital, Department of Pathology, 75013 Paris, France; (J.A.); (E.D.M.)
| | - Elisabeth Da Maïa
- AP-HP, Pitié-Salpêtrière Hospital, Department of Pathology, 75013 Paris, France; (J.A.); (E.D.M.)
| | - Alix Penel
- AP-HP, Pitié-Salpêtrière Hospital, Centre de Pharmaco-épidémiologie de l’APHP (CEPHEPI), 75013 Paris, France;
| | - Jérémie Belghiti
- Department of Gynecological and Breast Surgery and Oncology, Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié-Salpêtrière University Hospital, 75013 Paris, France; (M.C.); (J.B.); (M.N.); (C.G.); (G.C.); (C.U.)
| | - Marianne Nikpayam
- Department of Gynecological and Breast Surgery and Oncology, Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié-Salpêtrière University Hospital, 75013 Paris, France; (M.C.); (J.B.); (M.N.); (C.G.); (G.C.); (C.U.)
| | - Clémentine Gonthier
- Department of Gynecological and Breast Surgery and Oncology, Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié-Salpêtrière University Hospital, 75013 Paris, France; (M.C.); (J.B.); (M.N.); (C.G.); (G.C.); (C.U.)
| | - Laurine Ziane
- U1189-ONCO-THAI-Laser Assisted Therapy and Immunotherapies for On-cology, CHU Lille, Université de Lille, INSERM, F-59000 Lille, France; (A.-S.V.-D.); (L.Z.); (S.M.); (P.C.)
| | - Serge Mordon
- U1189-ONCO-THAI-Laser Assisted Therapy and Immunotherapies for On-cology, CHU Lille, Université de Lille, INSERM, F-59000 Lille, France; (A.-S.V.-D.); (L.Z.); (S.M.); (P.C.)
| | - Pierre Collinet
- U1189-ONCO-THAI-Laser Assisted Therapy and Immunotherapies for On-cology, CHU Lille, Université de Lille, INSERM, F-59000 Lille, France; (A.-S.V.-D.); (L.Z.); (S.M.); (P.C.)
- CHRU Lille, Jeanne de Flandre Hospital, Department of Gynecology, 59000 Lille, France
| | - Geoffroy Canlorbe
- Department of Gynecological and Breast Surgery and Oncology, Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié-Salpêtrière University Hospital, 75013 Paris, France; (M.C.); (J.B.); (M.N.); (C.G.); (G.C.); (C.U.)
- Cancer Biology and Therapeutics, Centre de Recherche Saint-Antoine (CRSA), Sorbonne University, INSERM UMR_S_938, 75020 Paris, France
- Institut Universitaire de Cancérologie (IUC), Sorbonne University, 75013 Paris, France
| | - Catherine Uzan
- Department of Gynecological and Breast Surgery and Oncology, Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié-Salpêtrière University Hospital, 75013 Paris, France; (M.C.); (J.B.); (M.N.); (C.G.); (G.C.); (C.U.)
- Cancer Biology and Therapeutics, Centre de Recherche Saint-Antoine (CRSA), Sorbonne University, INSERM UMR_S_938, 75020 Paris, France
- Institut Universitaire de Cancérologie (IUC), Sorbonne University, 75013 Paris, France
| |
Collapse
|
12
|
Champeau M, Jary D, Vignion-Dewalle AS, Mordon S, de Lassalle EM, Vignoud S, Mortier L. Introduction of a model of skin lesions on rats and testing of dissolving microneedles containing 5-aminolevulinic acid. Int J Pharm 2020; 594:120115. [PMID: 33359668 DOI: 10.1016/j.ijpharm.2020.120115] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2020] [Revised: 11/18/2020] [Accepted: 11/20/2020] [Indexed: 10/22/2022]
Abstract
Topical photodynamic therapy (PDT) is widely used to treat non melanoma skin cancers. It consists of topically applying on the skin lesions a cream containing a prodrug (5-aminolevulinic acid (5-ALA) or methyl aminolevulinate (MAL)) that is then metabolized to the photosensitizer protoporphyrin IX (PpIX). Light irradiation at PpIX excitation wavelength combined with oxygen then lead to a photochemical reaction inducing cell death. Nevertheless, this conventional PDT treatment is currently restricted to superficial skin lesions since the penetration depth of the prodrug is limited and hampers the production of PpIX in deep seated lesions. To overcome this problem, dissolving microneedles (MNs) included in a square flexible patch were developed. This easy-to-handle MN-patch is composed of 5-ALA mixed with hyaluronic acid (HA) and has the ability to dissolve after skin application. To evaluate the efficiency of this MN-patch in vivo, a skin lesion model has been developed on rats by applying UV-B illuminations. After 40 UV-B illuminations, histological and pharmacokinetic controls confirmed that the rats presented skin lesions. Once the rat skin lesion model has been validated, it was demonstrated that the MNs penetrated into the skin and fully dissolved in one hour on most of the rats. After one hour, the fluorescence images showed that the MN-patch produced a consequent and homogeneous level of PpIX. Overall, the dissolving MN-patch is a recent technology that has interesting features and several preclinical investigations should be led to compare its efficiency to that of the conventional treatment for PDT of non melanoma skin cancers.
Collapse
Affiliation(s)
- Mathilde Champeau
- CEA, LETI-DTBS, 17 rue des Martyrs, Grenoble Cedex, France; Univ. Lille, Inserm, CHU Lille, U1189 - ONCO-THAI - Assisted Laser Therapy and Immunotherapy for Oncology, F-59000 Lille, France.
| | - Dorothée Jary
- CEA, LETI-DTBS, 17 rue des Martyrs, Grenoble Cedex, France.
| | - Anne-Sophie Vignion-Dewalle
- Univ. Lille, Inserm, CHU Lille, U1189 - ONCO-THAI - Assisted Laser Therapy and Immunotherapy for Oncology, F-59000 Lille, France
| | - Serge Mordon
- Univ. Lille, Inserm, CHU Lille, U1189 - ONCO-THAI - Assisted Laser Therapy and Immunotherapy for Oncology, F-59000 Lille, France
| | - Elisabeth Martin de Lassalle
- Pathology Institute, Pole of Biology, Pathology and Genetics of the CHRU (University Hospital Research Center), 59000 Lille, France
| | | | - Laurent Mortier
- Univ. Lille, Inserm, CHU Lille, U1189 - ONCO-THAI - Assisted Laser Therapy and Immunotherapy for Oncology, F-59000 Lille, France
| |
Collapse
|
13
|
Le Calvé C, Abi Rached H, Vicentini C, Maire C, Lecomte F, Thecua E, Ziane L, Mordon S, Staumont-Sallé D, Mortier L. Traitement d’une maladie de Paget vulvaire (MPV) par photothérapie dynamique (PDT) à l’aide d’un nouveau dispositif textile lumineux. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.256] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
14
|
Milhem C, Moralès O, Ingelaere C, Pasquier D, Mordon S, Mortier L, Mirabel X, Delhem N. Combination of High Dose Hypofractionated Radiotherapy with Anti-PD1 Single Dose Immunotherapy Leads to a Th1 Immune Activation Resulting in a Complete Clinical Response in a Melanoma Patient. Int J Mol Sci 2020; 21:ijms21186772. [PMID: 32942768 PMCID: PMC7555181 DOI: 10.3390/ijms21186772] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2020] [Revised: 09/04/2020] [Accepted: 09/08/2020] [Indexed: 12/17/2022] Open
Abstract
The development of immunotherapy has recently modified the anti-tumor therapeutic arsenal; particularly, immune checkpoint inhibitors have led to a significant increase in overall survival. The current challenge is now to select good responder patients by identifying early biomarkers to propose therapeutic combinations that potentiate the efficacy of the therapy. Here we report the case of a 60-year-old man with superficial melanoma treated with high-dose hypo fractionated radiotherapy (H-SRT) combined with a single dose of anti-PD1 immunotherapy (Nivolumab) for a metastatic lymph node recurrence due to cancer progression. In this study, we present the results obtained regarding the activation of the Th1 immune response after H-SRT treatment followed by anti PD-1 therapeutic protocol. These results were correlated with clinical data to identify potential immunological biomarkers of treatment efficacy. This exceptional case report shows that a combination of H-SRT with a single dose of anti-PD1 immunotherapy may allow a better activation of the immune response in favor of a complete clinical response.
Collapse
Affiliation(s)
- Clara Milhem
- INSERM, CHU-Lille, U1189—ONCO-THAI—Assisted Laser Therapy and Immunotherapy for Oncology, University of Lille, F-59000 Lille, France; (C.M.); (O.M.); (S.M.)
- Immune Insight, Institut de Biologie de Lille, 59021 Lille, France;
| | - Olivier Moralès
- INSERM, CHU-Lille, U1189—ONCO-THAI—Assisted Laser Therapy and Immunotherapy for Oncology, University of Lille, F-59000 Lille, France; (C.M.); (O.M.); (S.M.)
- CNRS UMS 3702, Institut de Biologie de Lille, 59021 Lille, France
| | - Céline Ingelaere
- Immune Insight, Institut de Biologie de Lille, 59021 Lille, France;
| | - David Pasquier
- Service de Radiothérapie, Centre Oscar Lambret, 59000 Lille, France;
| | - Serge Mordon
- INSERM, CHU-Lille, U1189—ONCO-THAI—Assisted Laser Therapy and Immunotherapy for Oncology, University of Lille, F-59000 Lille, France; (C.M.); (O.M.); (S.M.)
| | - Laurent Mortier
- Service de Dermatologie, Hôpital Huriez, 59000 Lille, France;
| | - Xavier Mirabel
- Service de Radiothérapie, Centre Oscar Lambret, 59000 Lille, France;
- Correspondence: (X.M.); (N.D.); Tel.: +33-3-20-29-55-26 (X.M.); +33-3-20-87-12-53 (N.D.); Fax: +33-3-20-87-10-19 (N.D.)
| | - Nadira Delhem
- INSERM, CHU-Lille, U1189—ONCO-THAI—Assisted Laser Therapy and Immunotherapy for Oncology, University of Lille, F-59000 Lille, France; (C.M.); (O.M.); (S.M.)
- Correspondence: (X.M.); (N.D.); Tel.: +33-3-20-29-55-26 (X.M.); +33-3-20-87-12-53 (N.D.); Fax: +33-3-20-87-10-19 (N.D.)
| |
Collapse
|
15
|
Champeau M, Jary D, Mortier L, Mordon S, Vignoud S. A facile fabrication of dissolving microneedles containing 5-aminolevulinic acid. Int J Pharm 2020; 586:119554. [DOI: 10.1016/j.ijpharm.2020.119554] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2020] [Revised: 06/12/2020] [Accepted: 06/13/2020] [Indexed: 01/30/2023]
|
16
|
Mordon S, Thécua E, Ziane L, Lecomte F, Deleporte P, Baert G, Vignion‐Dewalle A. Light emitting fabrics for photodynamic therapy: Technology, experimental and clinical applications. Translational Biophotonics 2020. [DOI: 10.1002/tbio.202000005] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Affiliation(s)
- Serge Mordon
- University of Lille, Inserm, CHU Lille, U1189 – OncoThAI –Laser Assisted Therapies and Immunotherapies for Oncology Lille France
| | - Elise Thécua
- University of Lille, Inserm, CHU Lille, U1189 – OncoThAI –Laser Assisted Therapies and Immunotherapies for Oncology Lille France
| | - Laurine Ziane
- University of Lille, Inserm, CHU Lille, U1189 – OncoThAI –Laser Assisted Therapies and Immunotherapies for Oncology Lille France
| | - Fabienne Lecomte
- University of Lille, Inserm, CHU Lille, U1189 – OncoThAI –Laser Assisted Therapies and Immunotherapies for Oncology Lille France
| | - Pascal Deleporte
- University of Lille, Inserm, CHU Lille, U1189 – OncoThAI –Laser Assisted Therapies and Immunotherapies for Oncology Lille France
| | - Grégory Baert
- University of Lille, Inserm, CHU Lille, U1189 – OncoThAI –Laser Assisted Therapies and Immunotherapies for Oncology Lille France
| | - Anne‐Sophie Vignion‐Dewalle
- University of Lille, Inserm, CHU Lille, U1189 – OncoThAI –Laser Assisted Therapies and Immunotherapies for Oncology Lille France
| |
Collapse
|
17
|
Mordon S. Painless and efficient ALA-PDT and MAL-PDT of actinic keratosis can be achieved by drastically reducing the drug-light interval. Dermatol Ther 2020; 33:e13423. [PMID: 32304125 DOI: 10.1111/dth.13423] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2020] [Revised: 04/03/2020] [Accepted: 04/13/2020] [Indexed: 11/28/2022]
Affiliation(s)
- Serge Mordon
- University of Lille, INSERM, CHU Lille, U1189-ONCO-THAI, Assisted Laser Therapy and Immunotherapy for Oncology, Lille, France
| |
Collapse
|
18
|
Baydoun M, Moralès O, Frochot C, Ludovic C, Leroux B, Thecua E, Ziane L, Grabarz A, Kumar A, de Schutter C, Collinet P, Azais H, Mordon S, Delhem N. Photodynamic Therapy Using a New Folate Receptor-Targeted Photosensitizer on Peritoneal Ovarian Cancer Cells Induces the Release of Extracellular Vesicles with Immunoactivating Properties. J Clin Med 2020; 9:jcm9041185. [PMID: 32326210 PMCID: PMC7230754 DOI: 10.3390/jcm9041185] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2020] [Revised: 04/11/2020] [Accepted: 04/12/2020] [Indexed: 12/12/2022] Open
Abstract
Often discovered at an advanced stage, ovarian cancer progresses to peritoneal carcinoma, which corresponds to the invasion of the serosa by multiple tumor implants. The current treatment is based on the combination of chemotherapy and tumor cytoreduction surgery. Despite the progress and standardization of surgical techniques combined with effective chemotherapy, post-treatment recurrences affect more than 60% of women in remission. Photodynamic therapy (PDT) has been particularly indicated for the treatment of superficial lesions on large surfaces and appears to be a relevant candidate for the treatment of microscopic intraperitoneal lesions and non-visible lesions. However, the impact of this therapy on immune cells remains unclear. Hence, the objective of this study is to validate the efficacy of a new photosensitizer [pyropheophorbide a-polyethylene glycol-folic acid (PS)] on human ovarian cancer cells and to assess the impact of the secretome of PDT-treated cells on human peripheral blood mononuclear cells (PBMC). We show that PS, upon illumination, can induce cell death of different ovarian tumor cells. Furthermore, PDT using this new PS seems to favor activation of the immune response by inducing the secretion of effective cytokines and inhibiting the pro-inflammatory and immunosuppressive ones, as well as releasing extracellular vesicles (EVs) prone to activating immune cells. Finally, we show that PDT can activate CD4+ and CD8+ T cells, resulting in a potential immunostimulating process. The results of this pilot study therefore indicate that PS-PDT treatment may not only be effective in rapidly and directly destroying target tumor cells but also promote the activation of an effective immune response; notably, by EVs. These data thus open up good prospects for the treatment of micrometastases of intraperitoneal ovarian carcinosis which are currently inoperable.
Collapse
Affiliation(s)
- Martha Baydoun
- Université de Lille, Faculté des Sciences et Technologies, INSERM, CHU-Lille, U1189-ONCO-THAI–Assisted Laser Therapy and Immunotherapy for Oncology, F-59000 Lille, France; (M.B.); (O.M.); (B.L.); (E.T.); (L.Z.); (A.G.); (A.K.); (C.d.S.); (P.C.); (H.A.)
| | - Olivier Moralès
- Université de Lille, Faculté des Sciences et Technologies, INSERM, CHU-Lille, U1189-ONCO-THAI–Assisted Laser Therapy and Immunotherapy for Oncology, F-59000 Lille, France; (M.B.); (O.M.); (B.L.); (E.T.); (L.Z.); (A.G.); (A.K.); (C.d.S.); (P.C.); (H.A.)
- CNRS UMS 3702, Institut de Biologie de Lille, 59 021 Lille, France
| | - Céline Frochot
- LGRGP, UMR-CNRS 7274, University of Lorraine, 54 001 Nancy, France; (C.F.); (C.L.)
| | - Colombeau Ludovic
- LGRGP, UMR-CNRS 7274, University of Lorraine, 54 001 Nancy, France; (C.F.); (C.L.)
| | - Bertrand Leroux
- Université de Lille, Faculté des Sciences et Technologies, INSERM, CHU-Lille, U1189-ONCO-THAI–Assisted Laser Therapy and Immunotherapy for Oncology, F-59000 Lille, France; (M.B.); (O.M.); (B.L.); (E.T.); (L.Z.); (A.G.); (A.K.); (C.d.S.); (P.C.); (H.A.)
| | - Elise Thecua
- Université de Lille, Faculté des Sciences et Technologies, INSERM, CHU-Lille, U1189-ONCO-THAI–Assisted Laser Therapy and Immunotherapy for Oncology, F-59000 Lille, France; (M.B.); (O.M.); (B.L.); (E.T.); (L.Z.); (A.G.); (A.K.); (C.d.S.); (P.C.); (H.A.)
| | - Laurine Ziane
- Université de Lille, Faculté des Sciences et Technologies, INSERM, CHU-Lille, U1189-ONCO-THAI–Assisted Laser Therapy and Immunotherapy for Oncology, F-59000 Lille, France; (M.B.); (O.M.); (B.L.); (E.T.); (L.Z.); (A.G.); (A.K.); (C.d.S.); (P.C.); (H.A.)
| | - Anne Grabarz
- Université de Lille, Faculté des Sciences et Technologies, INSERM, CHU-Lille, U1189-ONCO-THAI–Assisted Laser Therapy and Immunotherapy for Oncology, F-59000 Lille, France; (M.B.); (O.M.); (B.L.); (E.T.); (L.Z.); (A.G.); (A.K.); (C.d.S.); (P.C.); (H.A.)
- Unité de Gynécologie-Obstétrique, Hôpital Jeanne de Flandre, 59 000 CHU Lille, France
| | - Abhishek Kumar
- Université de Lille, Faculté des Sciences et Technologies, INSERM, CHU-Lille, U1189-ONCO-THAI–Assisted Laser Therapy and Immunotherapy for Oncology, F-59000 Lille, France; (M.B.); (O.M.); (B.L.); (E.T.); (L.Z.); (A.G.); (A.K.); (C.d.S.); (P.C.); (H.A.)
| | - Clémentine de Schutter
- Université de Lille, Faculté des Sciences et Technologies, INSERM, CHU-Lille, U1189-ONCO-THAI–Assisted Laser Therapy and Immunotherapy for Oncology, F-59000 Lille, France; (M.B.); (O.M.); (B.L.); (E.T.); (L.Z.); (A.G.); (A.K.); (C.d.S.); (P.C.); (H.A.)
| | - Pierre Collinet
- Université de Lille, Faculté des Sciences et Technologies, INSERM, CHU-Lille, U1189-ONCO-THAI–Assisted Laser Therapy and Immunotherapy for Oncology, F-59000 Lille, France; (M.B.); (O.M.); (B.L.); (E.T.); (L.Z.); (A.G.); (A.K.); (C.d.S.); (P.C.); (H.A.)
- Unité de Gynécologie-Obstétrique, Hôpital Jeanne de Flandre, 59 000 CHU Lille, France
| | - Henri Azais
- Université de Lille, Faculté des Sciences et Technologies, INSERM, CHU-Lille, U1189-ONCO-THAI–Assisted Laser Therapy and Immunotherapy for Oncology, F-59000 Lille, France; (M.B.); (O.M.); (B.L.); (E.T.); (L.Z.); (A.G.); (A.K.); (C.d.S.); (P.C.); (H.A.)
- Service de Chirurgie et Cancérologie Gynécologique et Mammaire, Hôpital de la Pitié-Salpêtrière, AP-HP, 75 013 Paris, France
| | - Serge Mordon
- Université de Lille, Faculté des Sciences et Technologies, INSERM, CHU-Lille, U1189-ONCO-THAI–Assisted Laser Therapy and Immunotherapy for Oncology, F-59000 Lille, France; (M.B.); (O.M.); (B.L.); (E.T.); (L.Z.); (A.G.); (A.K.); (C.d.S.); (P.C.); (H.A.)
- Correspondence: (S.M.); (N.D.); Tel./Fax: +33-32044-6708 (S.M.); Tel.: +33-3208-71253/1251 (N.D.); Fax: +33-32087-1019 (N.D.)
| | - Nadira Delhem
- Université de Lille, Faculté des Sciences et Technologies, INSERM, CHU-Lille, U1189-ONCO-THAI–Assisted Laser Therapy and Immunotherapy for Oncology, F-59000 Lille, France; (M.B.); (O.M.); (B.L.); (E.T.); (L.Z.); (A.G.); (A.K.); (C.d.S.); (P.C.); (H.A.)
- Correspondence: (S.M.); (N.D.); Tel./Fax: +33-32044-6708 (S.M.); Tel.: +33-3208-71253/1251 (N.D.); Fax: +33-32087-1019 (N.D.)
| |
Collapse
|
19
|
Dupont C, Vermandel M, Leroy HA, Quidet M, Lecomte F, Delhem N, Mordon S, Reyns N. INtraoperative photoDYnamic Therapy for GliOblastomas (INDYGO): Study Protocol for a Phase I Clinical Trial. Neurosurgery 2020; 84:E414-E419. [PMID: 30053213 DOI: 10.1093/neuros/nyy324] [Citation(s) in RCA: 59] [Impact Index Per Article: 14.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2018] [Accepted: 06/17/2018] [Indexed: 12/17/2022] Open
Abstract
BACKGROUND Glioblastoma (GBM) is characterized by marked proliferation, major infiltration, and poor prognosis. Despite current treatments, including surgery, radiation oncology, and chemotherapy, the overall median survival is 15 mo and the progression-free survival is 7 to 8 mo. Because of systematic relapse of the tumor, the improvement of local control remains an issue. In this context, photodynamic therapy (PDT) may offer a new treatment modality for GBM. OBJECTIVE To assess the feasibility of intraoperative PDT early after surgical resection of GBM without unacceptable and unexpected toxicities. METHODS The INDYGO clinical trial (INtraoperative photoDYnamic Therapy for GliOblastomas) treatment will be carried out in addition to the current standard of care (SOC) of glioblastoma: maximum resection surgery followed by concomitant radio-chemotherapy and adjuvant chemotherapy. PDT treatment will be delivered during surgery early, after the fluorescence-guided resection. Immunological responses and biomarkers will also be investigated during the follow-up. A total of 10 patients will be recruited during this study. EXPECTED OUTCOMES Clinical follow-up after the SOC with PDT is expected to be similar (no significant difference) to the SOC alone. DISCUSSION This INDYGO trial assesses the feasibility of intraoperative 5-aminolevulinic acid PDT, a novel seamless approach to treat GBM. The technology is easily embeddable within the reference treatment at a low-incremental cost. The safety of this new treatment modality is a preliminary requirement before a multicenter randomized clinical trial can be further conducted to assess local control improvement by treating infiltrating and nonresected GBM cells.
Collapse
Affiliation(s)
- Clément Dupont
- University of Lille, Inserm, CHU Lille, ONCO-THAI - Image Assisted Laser Therapy for Oncology, Lille, France
| | - Maximilien Vermandel
- University of Lille, Inserm, CHU Lille, ONCO-THAI - Image Assisted Laser Therapy for Oncology, Lille, France.,Department of Neurosurgery, University of Lille, CHU Lille, Lille, France
| | - Henri-Arthur Leroy
- University of Lille, Inserm, CHU Lille, ONCO-THAI - Image Assisted Laser Therapy for Oncology, Lille, France.,Department of Neurosurgery, University of Lille, CHU Lille, Lille, France
| | - Mathilde Quidet
- University of Lille, Inserm, CHU Lille, ONCO-THAI - Image Assisted Laser Therapy for Oncology, Lille, France.,Department of Neurosurgery, University of Lille, CHU Lille, Lille, France
| | - Fabienne Lecomte
- University of Lille, Inserm, CHU Lille, ONCO-THAI - Image Assisted Laser Therapy for Oncology, Lille, France
| | - Nadira Delhem
- Institut de biologie de Lille, Institut Pasteur de Lille, University of Lille, CNRS, Lille, France
| | - Serge Mordon
- University of Lille, Inserm, CHU Lille, ONCO-THAI - Image Assisted Laser Therapy for Oncology, Lille, France
| | - Nicolas Reyns
- University of Lille, Inserm, CHU Lille, ONCO-THAI - Image Assisted Laser Therapy for Oncology, Lille, France.,Department of Neurosurgery, University of Lille, CHU Lille, Lille, France
| |
Collapse
|
20
|
Azaïs H, Rebahi C, Baydoun M, Serouart B, Ziane L, Moralès O, Frochot C, Colombeau L, Thécua E, Collinet P, Delhem N, Mordon S. A global approach for the development of photodynamic therapy of peritoneal metastases regardless of their origin. Photodiagnosis Photodyn Ther 2020; 30:101683. [PMID: 32061747 DOI: 10.1016/j.pdpdt.2020.101683] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2019] [Revised: 01/14/2020] [Accepted: 02/03/2020] [Indexed: 02/04/2023]
Abstract
Surgical management of peritoneal metastases raises the problem of the theoretical spread of the entire peritoneal surface. Intraperitoneal photodynamic therapy (IntraPDT) has been limited by the lack of specificity of photosensitizers (PS) and difficulties to bring light into the abdominal cavity. Recent data in ovarian cancer may give development opportunities for IntraPDT. Intraperitoneal PDT could be an option but the level of evidence of research in this topic must increase. Our opinion is that the most important is to have a realistic idea of what we can objectively expect from PDT and the feasibility of its daily application. At the time of personalized medicine, it is mandatory to select population eligible for a targeted PS administration and who could benefit from the process. The design of a specific PS for each subtype of cancers seems essential to avoid side effects on healthy tissue. On the contrary, our progress on lighting solutions can be beneficial for all patients with an indication of IntraPDT regardless of the origin of PM. A common lighting system developed for all cancers eligible for IntraPDT could be adapted with light source of specific wavelength to activate dedicated PS.
Collapse
Affiliation(s)
- Henri Azaïs
- Univ. Lille. Inserm, CHU Lille, U1189, ONCO-THAI- Image Assisted Laser Therapy for Oncology, Lille, France.
| | - Christie Rebahi
- Univ. Lille. Inserm, CHU Lille, U1189, ONCO-THAI- Image Assisted Laser Therapy for Oncology, Lille, France
| | - Martha Baydoun
- CNRS, UMR8161, Institut de Biologie de Lille, University of Lille, Institut Pasteur de Lille, France
| | - Benjamin Serouart
- Univ. Lille. Inserm, CHU Lille, U1189, ONCO-THAI- Image Assisted Laser Therapy for Oncology, Lille, France
| | - Laurine Ziane
- Univ. Lille. Inserm, CHU Lille, U1189, ONCO-THAI- Image Assisted Laser Therapy for Oncology, Lille, France
| | - Olivier Moralès
- CNRS, UMR8161, Institut de Biologie de Lille, University of Lille, Institut Pasteur de Lille, France
| | - Céline Frochot
- LGRGP, UMR-CNRS 7274, University of Lorraine, Nancy, France
| | | | - Elise Thécua
- Univ. Lille. Inserm, CHU Lille, U1189, ONCO-THAI- Image Assisted Laser Therapy for Oncology, Lille, France
| | - Pierre Collinet
- Univ. Lille. Inserm, CHU Lille, U1189, ONCO-THAI- Image Assisted Laser Therapy for Oncology, Lille, France; Department of Gynecologic Surgery - University Hospital, Lille, France
| | - Nadira Delhem
- CNRS, UMR8161, Institut de Biologie de Lille, University of Lille, Institut Pasteur de Lille, France
| | - Serge Mordon
- Univ. Lille. Inserm, CHU Lille, U1189, ONCO-THAI- Image Assisted Laser Therapy for Oncology, Lille, France
| |
Collapse
|
21
|
Maire C, Vignion-Dewalle AS, Cartier H, Mordon S. Artificial white light photodynamic therapy for actinic keratosis: a study of 38 patients in private office practice. J Eur Acad Dermatol Venereol 2020; 34:e165-e167. [PMID: 31774198 DOI: 10.1111/jdv.16112] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- C Maire
- Univ. Lille, INSERM, CHU Lille, U1189 - ONCO-THAI - Image Assisted Laser Therapy for Oncology, Lille, France.,Centre Médical Saint Jean, Arras, France
| | - A S Vignion-Dewalle
- Univ. Lille, INSERM, CHU Lille, U1189 - ONCO-THAI - Image Assisted Laser Therapy for Oncology, Lille, France
| | - H Cartier
- Centre Médical Saint Jean, Arras, France
| | - S Mordon
- Univ. Lille, INSERM, CHU Lille, U1189 - ONCO-THAI - Image Assisted Laser Therapy for Oncology, Lille, France
| |
Collapse
|
22
|
Mordon S, Vignion-Dewalle A, Abi-Rached H, Thecua E, Lecomte F, Vicentini C, Deleporte P, Béhal H, Kerob D, Hommel T, Duhamel A, Szeimies R, Mortier L. Testing a new light therapy for the treatment of actinic keratosis. Br J Dermatol 2020. [DOI: 10.1111/bjd.18651] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
23
|
Mordon S, Vignion-Dewalle A, Abi-Rached H, Thecua E, Lecomte F, Vicentini C, Deleporte P, Béhal H, Kerob D, Hommel T, Duhamel A, Szeimies R, Mortier L. 测试一种用于治疗光化性角化症的新的光疗法. Br J Dermatol 2020. [DOI: 10.1111/bjd.18668] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
24
|
Lecomte F, Thecua E, Ziane L, Deleporte P, Duhamel A, Maire C, Staumont-Salle D, Mordon S, Mortier L. Photodynamic Therapy Using a New Painless Light-Emitting Fabrics Device in the Treatment of Extramammary Paget Disease of the Vulva (the PAGETEX Study): Protocol for an Interventional Efficacy and Safety Trial. JMIR Res Protoc 2019; 8:e15026. [PMID: 31793891 PMCID: PMC6918208 DOI: 10.2196/15026] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2019] [Accepted: 09/04/2019] [Indexed: 12/21/2022] Open
Abstract
Background Extramammary Paget disease of the vulva (EMPV) is a rare skin disorder commonly seen in postmenopausal Caucasian females that appears clinically as red, eczematous, pruriginous, and sometimes painful lesions. Although most cases are noninvasive, EMPV may be associated with an underlying or distant adenocarcinoma. EMPV has a chronic and relapsing course. The reference treatment is based on local surgical excision with negative margins. However, disease frequently extends far from the visible lesion, and surgical margins are frequently positive. Topical photodynamic therapy (PDT) is an established treatment modality for various dermatooncologic conditions. For example, red light irradiation with the Aktilite CL 128 and Metvixia (Galderma SA) as a photosensitizing molecule is a conventional protocol approved and widely used in Europe for PDT treatment of actinic keratosis, but this treatment is not yet widely used for EMPV because it has never clearly been demonstrated and is very painful. Objective The aim of the study is to investigate the efficacy and safety relating to the medical device PAGETEX as a new painless PDT device using Metvixia in the treatment of vulvar Paget disease. The primary end point is the disease control rate at 3 months in 30% of the patients included, defined as stability, partial response, or total response, considering the extent of the lesion. Secondary end points are the disease control rate at 6 months, patient quality of life, level of pain experienced by the patient at each PDT session, severity of erythema, presence of protoporphyrin IX in Paget cells after each PDT session, and overall satisfaction level of the patient. Methods The trial is an interventional, exploratory, simple group, nonrandomized, and single center (Lille University Hospital) study. Twenty-four patients will be included according to Simon’s optimal plan. Therapeutic procedure is based on a cycle of two PDT sessions with the PAGETEX medical device at 15-day intervals (Metvixia incubation during 30 minutes and 635 nm red light illumination with a low irradiance for 2 hours and 30 minutes for a total fluence of 12 J/cm²). At the assessment session, 3 months after inclusion, if the control of the disease is partial or null, the patient will complete another cycle of two PDT sessions. A final evaluation will be performed in all patients at 6 months. Analyses will be performed using SAS version 9.4 software (SAS Institute Inc). The characteristics of the patients at baseline will be described; qualitative variables will be described by numbers and percentages, and quantitative variables will be described either by the mean and standard deviation for Gaussian distribution or by the median and interquartile range (ie, 25th and 75th percentiles). The normality of the distributions will be tested by a Shapiro-Wilk test and checked graphically by histograms. Results First patient was included in September 2019 and clinical investigations are planned until August 2022. The final results of this study are expected to be available in January 2023. Conclusions This clinical trial aims to evaluate the efficacy and safety of a new PDT protocol for the treatment of EMPV. The PAGETEX device could become the treatment of choice if it is effective, painless, and easy to implement and use in hospitals. Trial Registration ClinicalTrials.gov NCT03713203; https://clinicaltrials.gov/ct2/show/NCT03713203 International Registered Report Identifier (IRRID) PRR1-10.2196/15026
Collapse
Affiliation(s)
- Fabienne Lecomte
- U1189 - Image Assisted Laser Therapies for Oncology, Inserm, Centre Hospitalier et Universitaire de Lille, Université de Lille, Lille, France
| | - Elise Thecua
- U1189 - Image Assisted Laser Therapies for Oncology, Inserm, Centre Hospitalier et Universitaire de Lille, Université de Lille, Lille, France
| | - Laurine Ziane
- U1189 - Image Assisted Laser Therapies for Oncology, Inserm, Centre Hospitalier et Universitaire de Lille, Université de Lille, Lille, France
| | - Pascal Deleporte
- U1189 - Image Assisted Laser Therapies for Oncology, Inserm, Centre Hospitalier et Universitaire de Lille, Université de Lille, Lille, France
| | - Alain Duhamel
- EA 2694 - Santé Publique: Epidémiologie et Qualité des Soins, Unité de Biostatistiques, Centre Hospitalier et Universitaire de Lille, Université de Lille, Lille, France
| | - Cyril Maire
- U1189 - Image Assisted Laser Therapies for Oncology, Inserm, Centre Hospitalier et Universitaire de Lille, Université de Lille, Lille, France.,Department of Dermatology, Centre Hospitalier et Universitaire de Lille, Lille, France
| | | | - Serge Mordon
- U1189 - Image Assisted Laser Therapies for Oncology, Inserm, Centre Hospitalier et Universitaire de Lille, Université de Lille, Lille, France
| | - Laurent Mortier
- U1189 - Image Assisted Laser Therapies for Oncology, Inserm, Centre Hospitalier et Universitaire de Lille, Université de Lille, Lille, France.,Department of Dermatology, Centre Hospitalier et Universitaire de Lille, Lille, France
| |
Collapse
|
25
|
Abi Rached H, Mordon S, Vicentini C, Maire C, Thecua E, Lecomte F, Vignon AS, Deleporte P, Szeimies PM, Mortier L. Étude de phase II évaluant la non-infériorité et la tolérance du dispositif textile lumineux PHOS-ISTOS® comparé à la photothérapie dynamique conventionnelle : un essai randomisé, contrôlé, bi-centrique. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
26
|
Dubois M, Abi Rached H, Vicentini C, Maire C, Mordon S, Mortier L. Traitement des kératoses actiniques du cuir chevelu par le dispositif de photothérapie dynamique textile Fluxmedicare® : évaluation en vraie vie sur 32 patients. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.247] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
27
|
Mordon S, Vignion-Dewalle AS, Abi-Rached H, Thecua E, Lecomte F, Vicentini C, Deleporte P, Béhal H, Kerob D, Hommel T, Duhamel A, Szeimies RM, Mortier L. The conventional protocol vs. a protocol including illumination with a fabric-based biophotonic device (the Phosistos protocol) in photodynamic therapy for actinic keratosis: a randomized, controlled, noninferiority clinical study. Br J Dermatol 2019; 182:76-84. [PMID: 31021404 DOI: 10.1111/bjd.18048] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/24/2019] [Indexed: 12/22/2022]
Abstract
BACKGROUND Topical photodynamic therapy (PDT) using methyl aminolaevulinate is a noninvasive treatment option suitable to treat clinical and subclinical actinic keratosis (AK) over a large area (field cancerization). The most widely used, conventional protocol in Europe includes illumination with a red-light lamp. This illumination commonly causes pain, and patients often cannot complete the treatment. OBJECTIVES The aims of this paper are twofold. The first aim is to introduce a novel protocol, the Phosistos protocol (P-PDT), which includes illumination with a fabric-based biophotonic device. The second and major aim is to assess the noninferiority, in terms of efficacy for PDT of AK, of P-PDT compared with the conventional protocol (C-PDT). METHODS A randomized, controlled, multicentre, intraindividual clinical study was conducted. Forty-six patients with grade I-II AK of the forehead and scalp were treated with P-PDT on one area (280 AK lesions) and with C-PDT on the contralateral area (280 AK lesions). The primary end point was the lesion complete response (CR) rate at 3 months, with an absolute noninferiority margin of -10%. Secondary end points included pain scores, incidence of adverse effects and cosmetic outcome. RESULTS Three months following treatment, the lesion CR rate of P-PDT was noninferior to that of C-PDT (79·3% vs. 80·7%, respectively; absolute difference -1·6%; one-sided 95% confidence interval -4·5% to infinity). The noninferiority of P-PDT to C-PDT in terms of the lesion CR rate remained at the 6-month follow-up (94·2% vs. 94·9%, respectively; absolute difference -0·6%; one-sided 95% confidence interval -2·7% to infinity). Moreover, the pain score at the end of illumination was significantly lower for P-PDT than for C-PDT (mean ± SD 0·3 ± 0·6 vs. 7·4 ± 2·3; P < 0·001). CONCLUSIONS P-PDT is noninferior to C-PDT in terms of efficacy for treating AK of the forehead and scalp and resulted in much lower pain scores and fewer adverse effects. What's already known about this topic? Topical photodynamic therapy using methyl aminolaevulinate is effective for treating actinic keratosis. In Europe, the conventional protocol involves illumination with a red-light lamp. Unfortunately, pain is often experienced by patients undergoing this protocol. An alternative protocol that uses daylight illumination has recently been shown to be as effective as the conventional protocol while being nearly painless. However, this alternative protocol can be conducted only in suitable weather conditions. What does this study add? The Phosistos protocol is demonstrated to be as effective as the conventional protocol, nearly as painless as the daylight protocols and suitable year round for treatment of actinic keratosis.
Collapse
Affiliation(s)
- S Mordon
- University of Lille, INSERM, CHU Lille, U1189 - ONCO-THAI - Image Assisted Laser Therapy for Oncology, F-59000, Lille, France
| | - A S Vignion-Dewalle
- University of Lille, INSERM, CHU Lille, U1189 - ONCO-THAI - Image Assisted Laser Therapy for Oncology, F-59000, Lille, France
| | - H Abi-Rached
- University of Lille, INSERM, CHU Lille, U1189 - ONCO-THAI - Image Assisted Laser Therapy for Oncology, F-59000, Lille, France.,Department of Dermatology, CHU Lille, F-59000, Lille, France
| | - E Thecua
- University of Lille, INSERM, CHU Lille, U1189 - ONCO-THAI - Image Assisted Laser Therapy for Oncology, F-59000, Lille, France
| | - F Lecomte
- University of Lille, INSERM, CHU Lille, U1189 - ONCO-THAI - Image Assisted Laser Therapy for Oncology, F-59000, Lille, France
| | - C Vicentini
- University of Lille, INSERM, CHU Lille, U1189 - ONCO-THAI - Image Assisted Laser Therapy for Oncology, F-59000, Lille, France.,Department of Dermatology, CHU Lille, F-59000, Lille, France
| | - P Deleporte
- University of Lille, INSERM, CHU Lille, U1189 - ONCO-THAI - Image Assisted Laser Therapy for Oncology, F-59000, Lille, France
| | - H Béhal
- University of Lille, CHU Lille, EA 2694 - Santé Publique: Epidémiologie et Qualité des Soins, Unité de Biostatistiques, F-59000, Lille, France
| | - D Kerob
- Galderma International SAS, F-92927, La Défense, France
| | - T Hommel
- Department of Dermatology and Allergology, Klinikum Vest GmbH, D-45657, Recklinghausen, Germany
| | - A Duhamel
- University of Lille, CHU Lille, EA 2694 - Santé Publique: Epidémiologie et Qualité des Soins, Unité de Biostatistiques, F-59000, Lille, France
| | - R M Szeimies
- Department of Dermatology and Allergology, Klinikum Vest GmbH, D-45657, Recklinghausen, Germany
| | - L Mortier
- University of Lille, INSERM, CHU Lille, U1189 - ONCO-THAI - Image Assisted Laser Therapy for Oncology, F-59000, Lille, France.,Department of Dermatology, CHU Lille, F-59000, Lille, France
| |
Collapse
|
28
|
Champeau M, Vignoud S, Mortier L, Mordon S. Photodynamic therapy for skin cancer: How to enhance drug penetration? J Photochem Photobiol B 2019; 197:111544. [PMID: 31295716 DOI: 10.1016/j.jphotobiol.2019.111544] [Citation(s) in RCA: 51] [Impact Index Per Article: 10.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/12/2018] [Revised: 06/14/2019] [Accepted: 06/25/2019] [Indexed: 12/27/2022]
Abstract
Photodynamic therapy (PDT) induced by protoporphyrin IX (PpIX) has been widely used in dermatological practices such as treatment of skin cancers. Clearance rate depends on different factors such as light irradiation, skin oxygenation and drug penetration. The poor penetration of 5-aminolevulinic acid (5-ALA) with topical application is limited and restrains the production of PpIX which could restrict PDT outcomes. This review will focus on techniques already used to enhance drug penetration in human skin, and will present their results, advantages, and drawbacks. Chemical and physical pretreatments will be discussed. Chemical pre-treatments comprise of drug formulation modification, use of agents that modify the heme cycle, enhance PpIX formation, and the combination of differentiation-promoting agent prior to PDT. On the other hand, physical pretreatments affect the skin barrier by creating holes in the skin or by removing stratum corneum. To promote drug penetration, iontophoresis and temperature modulation are interesting alternative methods. Cellular mechanisms enrolled during chemical or physical pretreatments have been investigated in order to understand how 5-ALA penetrates the skin, why it is preferentially metabolized in PpIX in tumour cells, and how it could be accumulated in deeper skin layers. The objective of this review is to compare clinical trials that use innovative technology to conventional PDT treatment. Most of these pretreatments present good or even better clinical outcomes than usual PDT.
Collapse
Affiliation(s)
- Mathilde Champeau
- LETI-DTBS, CEA, 17 rue des Martyrs, Grenoble Cedex, France; U1189 - ONCO-THAI - Image Assisted Laser Therapy for Oncology, CHU Lille, Univ. Lille, Inserm, F-59000 Lille, France.
| | | | - Laurent Mortier
- U1189 - ONCO-THAI - Image Assisted Laser Therapy for Oncology, CHU Lille, Univ. Lille, Inserm, F-59000 Lille, France
| | - Serge Mordon
- U1189 - ONCO-THAI - Image Assisted Laser Therapy for Oncology, CHU Lille, Univ. Lille, Inserm, F-59000 Lille, France
| |
Collapse
|
29
|
Dupont C, Baert G, Mordon S, Vermandel M. Parallelized Monte-Carlo dosimetry using graphics processing units to model cylindrical diffusers used in photodynamic therapy: From implementation to validation. Photodiagnosis Photodyn Ther 2019; 26:351-360. [DOI: 10.1016/j.pdpdt.2019.04.020] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2018] [Revised: 04/12/2019] [Accepted: 04/19/2019] [Indexed: 12/28/2022]
|
30
|
Abstract
Photodynamic therapy has become of interest in many European countries. Since, most of national authorities and all medical journals require the registration of the clinical study on the database ClinicalTrials. gov in order to be published, information regarding clinical studies are now available. This article aims to synthetize data gathered thanks to this database. The keywords used for this analysis was: (i) status: “All studies “(recruiting, completed, terminated, we did not take into account unknown status), (ii) condition or disease: “Photodynamic Therapy”, (iii) country: name of each European country. Since 2003, 76 clinical trials were registered in Europe. Most clinical studies are performed in Germany (22), France (20) and UK (19). These 3 countries represent 80% of all studies performed in Europe. However 21 European countries have one or more studies on PDT. Clinical studies were mainly performed on skin. Actinic Keratosis treatment (20 studies) represents more than 45% of all studies. 21% were focused on eye, mainly on Age Macular Degeneration (AMD) (8 studies). In 2018, ten (10) clinical trials are in the recruitment phase. On November, 10, 2017, Padeliporfin (STEBA Biotech S.A, Luxembourg) obtained the marketing authorization throughout the European Union. Despite the critical importance of trial registration, compliance with requirements from governmental regulators which mandate the prospective registration of clinical trials has been imperfect. Besides, a large proportion of registry entries are never updated to reflect study completion. However, this review clearly demonstrated that PDT is progressively used in most European countries.
Collapse
Affiliation(s)
- Céline Frochot
- Laboratoire Réactions et Génie des Procédés, UMR 7274 CNRS-Lorraine University, 1 Rue Grandville, 54000 Nancy, France
| | - Serge Mordon
- Université de Lille, INSERM, CHU Lille, U1189 ONCO-THAI, Image Assisted Laser Therapy for Oncology, F-59000 Lille, France
| |
Collapse
|
31
|
Mordon S, Vignion‐Dewalle AS. Low‐irradiance red light compared to conventional red light in photodynamic therapy of actinic keratosis: A way to reduce pain during treatment. Dermatol Ther 2019; 32:e12913. [DOI: 10.1111/dth.12913] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2019] [Revised: 03/27/2019] [Accepted: 04/05/2019] [Indexed: 11/30/2022]
Affiliation(s)
- Serge Mordon
- INSERM, Univ. Lille, CHU Lille, U1189‐OncoThAI, Image Assisted Laser Therapy for Oncology Lille France
| | - Anne S. Vignion‐Dewalle
- INSERM, Univ. Lille, CHU Lille, U1189‐OncoThAI, Image Assisted Laser Therapy for Oncology Lille France
| |
Collapse
|
32
|
Lecomte F, Vignion-Dewalle AS, Vicentini C, Thecua E, Deleporte P, Duhamel A, Mordon S, Mortier L. Evaluating the Noninferiority of a New Photodynamic Therapy (Flexitheralight) Compared With Conventional Treatment for Actinic Keratosis: Protocol for a Phase 2 Study. JMIR Res Protoc 2019; 8:e11530. [PMID: 31025952 PMCID: PMC6658309 DOI: 10.2196/11530] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2018] [Revised: 09/28/2018] [Accepted: 10/15/2018] [Indexed: 12/19/2022] Open
Abstract
Background Actinic keratosis (AK) is characterized by preinvasive, cancerous lesions on sun-exposed skin that negatively affect patient quality of life and may progress to invasive squamous cell carcinoma (SCC). If untreated, AK may either regress or progress to SCC, with significant morbidity and possible lethal outcomes. The most commonly used treatments for AK are cryotherapy, topical chemotherapy and, more recently, photodynamic therapy (PDT). This clinical study is part of a project that aims to create specific light-emitting fabrics (LEFs) that strongly improve the efficiency and reliability of PDT as a treatment for AK. Objective This study aims to compare the efficacy and tolerability of a new PDT protocol involving the Flexitheralight device (N-PDT) with the classical protocol involving the Aktilite CL 128 device (C-PDT; Galderma Laboratories) for the treatment of AK. All participants receive both protocols. The primary objective of this study is to compare the lesion response rate after 3 months of N-PDT with C-PDT. Secondary objectives are evaluations of pain and local tolerance during treatment, clinical evolution of the subject's skin, and evaluations of patient quality of life and satisfaction. Methods The study is a split-face, intraindividual comparison of two PDT protocols. The total number of patients recruited was 42. Patients were exposed to a continuous red light with the Aktilite CL 128 device on one side of the face and to fractionated red illumination with the new device, Flexitheralight, on the other side of the face. Males or females over the age of 18 years with a clinical diagnosis of at least 10 previously untreated, nonpigmented, nonhyperkeratotic grade I and II AK lesions of the forehead and/or scalp were included and were recruited from the Department of Dermatology of the Centre Hospitalier Universitaire de Lille. The patients came to the investigational center for one treatment session (day 1), and they were followed up after 7 days, 3 months and 6 months. A second treatment session was performed on day 111 in cases in which an incomplete response was observed at the 3-month follow-up. Data will be analyzed using SAS software version 9.4 (SAS Institute Inc). Continuous variables will be reported as means and standard deviations, and categorical variables will be reported as frequencies and percentages. The Shapiro-Wilk test will be used to assess the normality of the distribution. Results The clinical investigation was performed by July 2018. Data analysis was performed at the end of 2018, and results are expected to be published in early 2019. Conclusions This phase II clinical trial aims to evaluate the noninferior efficacy and superior tolerability of N-PDT compared to that of C-PDT. If N-PDT is both efficacious and tolerable, N-PDT could become the treatment of choice for AK due to its ease of implementation in hospitals. Trial Registration ClinicalTrials.gov NCT03076918; https://clinicaltrials.gov/ct2/show/NCT03076918 (archived by WebCite at http://www.webcitation.org/771KA0SSK) International Registered Report Identifier (IRRID) DERR1-10.2196/11530
Collapse
Affiliation(s)
- Fabienne Lecomte
- U1189 - Image Assisted Laser Therapies for Oncology, Inserm, Centre Hospitalier et Universitaire de Lille, Université de Lille, Lille, France
| | - Anne Sophie Vignion-Dewalle
- U1189 - Image Assisted Laser Therapies for Oncology, Inserm, Centre Hospitalier et Universitaire de Lille, Université de Lille, Lille, France
| | - Claire Vicentini
- U1189 - Image Assisted Laser Therapies for Oncology, Inserm, Centre Hospitalier et Universitaire de Lille, Université de Lille, Lille, France.,Department of Dermatology, Centre Hospitalier et Universitaire de Lille, Université de Lille, Lille, France
| | - Elise Thecua
- U1189 - Image Assisted Laser Therapies for Oncology, Inserm, Centre Hospitalier et Universitaire de Lille, Université de Lille, Lille, France
| | - Pascal Deleporte
- U1189 - Image Assisted Laser Therapies for Oncology, Inserm, Centre Hospitalier et Universitaire de Lille, Université de Lille, Lille, France
| | - Alain Duhamel
- EA 2694 - Santé Publique: épidémiologie et Qualité des Soins, Unité de Biostatistiques, Centre Hospitalier et Universitaire de Lille, Université de Lille, Lille, France
| | - Serge Mordon
- U1189 - Image Assisted Laser Therapies for Oncology, Inserm, Centre Hospitalier et Universitaire de Lille, Université de Lille, Lille, France
| | - Laurent Mortier
- U1189 - Image Assisted Laser Therapies for Oncology, Inserm, Centre Hospitalier et Universitaire de Lille, Université de Lille, Lille, France.,Department of Dermatology, Centre Hospitalier et Universitaire de Lille, Université de Lille, Lille, France
| |
Collapse
|
33
|
Vignion-Dewalle AS, Abi Rached H, Thecua E, Lecomte F, Deleporte P, Béhal H, Hommel T, Duhamel A, Szeimies RM, Mortier L, Mordon S. A New Light-Emitting, Fabric-Based Device for Photodynamic Therapy of Actinic Keratosis: Protocol for a Randomized, Controlled, Multicenter, Intra-Individual, Phase II Noninferiority Study (the Phosistos Study). JMIR Res Protoc 2019; 8:e12990. [PMID: 31025953 PMCID: PMC6658310 DOI: 10.2196/12990] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2018] [Revised: 02/04/2019] [Accepted: 02/07/2019] [Indexed: 01/19/2023] Open
Abstract
BACKGROUND Actinic keratosis (AK) is a common early in situ skin carcinoma caused by long-term sun exposure and usually develops on sun-exposed skin areas. Left untreated, AK may progress to squamous cell carcinoma. To prevent such risk, most clinicians routinely treat AK. Therapy options for AK include cryotherapy, topical treatments, curettage, excision surgery, and photodynamic therapy (PDT). OBJECTIVE The aim of this study is to assess the noninferiority, in terms of efficacy at 3 months, of a PDT protocol involving a new light-emitting device (PDT using the Phosistos protocol [P-PDT]) compared with the conventional protocol (PDT using the conventional protocol [C-PDT]) in the treatment of AK. METHODS In this randomized, controlled, multicenter, intra-individual, phase II noninferiority clinical study, subjects with AK of the forehead and scalp are treated with P-PDT on one area and with C-PDT on the contralateral area. In both areas, lesions are prepared and methyl aminolevulinate (MAL) is applied. Thirty minutes after MAL application, the P-PDT area is exposed to red light at low irradiance (1.3 mW/cm2) for 2.5 hours so that a light dose of 12 J/cm2 is achieved. In the control area (C-PDT area), a 37 J/cm2 red light irradiation is performed 3 hours after MAL application. Recurrent AK at 3 months is retreated. The primary end point is the lesion complete response rate at 3 months. Secondary end points include pain scores at 1 day, local tolerance at 7 days, lesion complete response rate at 6 months, cosmetic outcome at 3 and 6 months, and patient-reported quality of life and satisfaction throughout the study. A total of 45 patients needs to be recruited. RESULTS Clinical investigations are complete: 46 patients were treated with P-PDT on one area (n=285 AK) and with C-PDT on the contralateral area (n=285 AK). Data analysis is ongoing, and statistical results will be available in the first half of 2019. CONCLUSIONS In case of noninferiority in efficacy and superiority in tolerability of P-PDT compared with C-PDT, P-PDT could become the treatment of choice for AK. TRIAL REGISTRATION ClinicalTrials.gov NCT03076892; https://clinicaltrials.gov/ct2/show/NCT03076892 (Archived by WebCite at http://www.webcitation.org/779qqVKek). INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) DERR1-10.2196/12990.
Collapse
Affiliation(s)
- Anne-Sophie Vignion-Dewalle
- U1189 - ONCO-THAI - Image Assisted Laser Therapy for Oncology, Université de Lille, INSERM, Centre Hospitalier Universitaire de Lille, Lille, France
| | - Henry Abi Rached
- U1189 - ONCO-THAI - Image Assisted Laser Therapy for Oncology, Université de Lille, INSERM, Centre Hospitalier Universitaire de Lille, Lille, France.,Department of Dermatology, Centre Hospitalier Universitaire de Lille, Lille, France
| | - Elise Thecua
- U1189 - ONCO-THAI - Image Assisted Laser Therapy for Oncology, Université de Lille, INSERM, Centre Hospitalier Universitaire de Lille, Lille, France
| | - Fabienne Lecomte
- U1189 - ONCO-THAI - Image Assisted Laser Therapy for Oncology, Université de Lille, INSERM, Centre Hospitalier Universitaire de Lille, Lille, France
| | - Pascal Deleporte
- U1189 - ONCO-THAI - Image Assisted Laser Therapy for Oncology, Université de Lille, INSERM, Centre Hospitalier Universitaire de Lille, Lille, France
| | - Hélène Béhal
- EA 2694 - Santé Publique: épidémiologie et qualité des soins, Unité de Biostatistiques, Université de Lille, Centre Hospitalier Universitaire de Lille, Lille, France
| | - Theresa Hommel
- Department of Dermatology and Allergology, Klinikum Vest GmbH, Recklinghausen, Germany
| | - Alain Duhamel
- EA 2694 - Santé Publique: épidémiologie et qualité des soins, Unité de Biostatistiques, Université de Lille, Centre Hospitalier Universitaire de Lille, Lille, France
| | - Rolf-Markus Szeimies
- Department of Dermatology and Allergology, Klinikum Vest GmbH, Recklinghausen, Germany
| | - Laurent Mortier
- U1189 - ONCO-THAI - Image Assisted Laser Therapy for Oncology, Université de Lille, INSERM, Centre Hospitalier Universitaire de Lille, Lille, France.,Department of Dermatology, Centre Hospitalier Universitaire de Lille, Lille, France
| | - Serge Mordon
- U1189 - ONCO-THAI - Image Assisted Laser Therapy for Oncology, Université de Lille, INSERM, Centre Hospitalier Universitaire de Lille, Lille, France
| |
Collapse
|
34
|
Vicentini C, Vignion‐Dewalle A, Thecua E, Lecomte F, Maire C, Deleporte P, Béhal H, Kerob D, Duhamel A, Mordon S, Mortier L. A new protocol using a light‐emitting fabric for PDT of AK. Br J Dermatol 2019. [DOI: 10.1111/bjd.17655] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
35
|
Vicentini C, Vignion‐Dewalle A, Thecua E, Lecomte F, Maire C, Deleporte P, Béhal H, Kerob D, Duhamel A, Mordon S, Mortier L. 一种利用发光纤维进行 AK PDT 的新方案. Br J Dermatol 2019. [DOI: 10.1111/bjd.17671] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
36
|
Vicentini C, Vignion-Dewalle AS, Thecua E, Lecomte F, Béhal H, Maire C, Tylcz JB, Abi-Rached H, Mortier L, Mordon S. Photodynamic therapy for actinic keratosis of the forehead and scalp with the Aktilite CL 128: Is there a cut-off value for PpIX-weighted irradiance for effective treatment? Photodermatol Photoimmunol Photomed 2019; 35:232-237. [DOI: 10.1111/phpp.12457] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/21/2018] [Revised: 01/22/2019] [Accepted: 02/10/2019] [Indexed: 11/30/2022]
Affiliation(s)
- Claire Vicentini
- Univ. Lille, INSERM, CHU Lille; U1189 - ONCO-THAI - Image Assisted Laser Therapy for Oncology; Lille France
- Department of Dermatology; CHU Lille; Lille France
| | | | - Elise Thecua
- Univ. Lille, INSERM, CHU Lille; U1189 - ONCO-THAI - Image Assisted Laser Therapy for Oncology; Lille France
| | - Fabienne Lecomte
- Univ. Lille, INSERM, CHU Lille; U1189 - ONCO-THAI - Image Assisted Laser Therapy for Oncology; Lille France
| | - Hélène Béhal
- Univ. Lille, CHU Lille; EA 2694 - Santé Publique: épidémiologie et qualité des soins; Unité de Biostatistiques; Lille France
| | - Cyril Maire
- Univ. Lille, INSERM, CHU Lille; U1189 - ONCO-THAI - Image Assisted Laser Therapy for Oncology; Lille France
- Department of Dermatology; CHU Lille; Lille France
| | - Jean-Baptiste Tylcz
- Univ. Lille, INSERM, CHU Lille; U1189 - ONCO-THAI - Image Assisted Laser Therapy for Oncology; Lille France
| | - Henry Abi-Rached
- Univ. Lille, INSERM, CHU Lille; U1189 - ONCO-THAI - Image Assisted Laser Therapy for Oncology; Lille France
- Department of Dermatology; CHU Lille; Lille France
| | - Laurent Mortier
- Univ. Lille, INSERM, CHU Lille; U1189 - ONCO-THAI - Image Assisted Laser Therapy for Oncology; Lille France
- Department of Dermatology; CHU Lille; Lille France
| | - Serge Mordon
- Univ. Lille, INSERM, CHU Lille; U1189 - ONCO-THAI - Image Assisted Laser Therapy for Oncology; Lille France
| |
Collapse
|
37
|
Azaïs H, Delhem N, Frochot C, Colombeau L, Grabarz A, Moralès O, Mordon S, Collinet P. Photodynamic therapy of peritoneal metastases of ovarian cancer to improve microscopic cytoreduction and to enhance antitumoral immunity. Eur J Obstet Gynecol Reprod Biol 2019. [DOI: 10.1016/j.ejogrb.2018.08.556] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
38
|
Vicentini C, Vignion‐Dewalle A, Thecua E, Lecomte F, Maire C, Deleporte P, Béhal H, Kerob D, Duhamel A, Mordon S, Mortier L. Photodynamic therapy for actinic keratosis of the forehead and scalp: a randomized, controlled, phaseIIclinical study evaluating the noninferiority of a new protocol involving irradiation with a light‐emitting, fabric‐based device (the Flexitheralight protocol) compared with the conventional protocol involving irradiation with the AktiliteCL128 lamp. Br J Dermatol 2019; 180:765-773. [DOI: 10.1111/bjd.17350] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/24/2018] [Indexed: 11/30/2022]
Affiliation(s)
- C. Vicentini
- Univ. Lille INSERM, CHU Lille, U1189 – ONCO‐THAI – Image Assisted Laser Therapy for Oncology F‐59000 LilleFrance
- Department of Dermatology CHU Lille F‐59000 LilleFrance
| | - A.S. Vignion‐Dewalle
- Univ. Lille INSERM, CHU Lille, U1189 – ONCO‐THAI – Image Assisted Laser Therapy for Oncology F‐59000 LilleFrance
| | - E. Thecua
- Univ. Lille INSERM, CHU Lille, U1189 – ONCO‐THAI – Image Assisted Laser Therapy for Oncology F‐59000 LilleFrance
| | - F. Lecomte
- Univ. Lille INSERM, CHU Lille, U1189 – ONCO‐THAI – Image Assisted Laser Therapy for Oncology F‐59000 LilleFrance
| | - C. Maire
- Univ. Lille INSERM, CHU Lille, U1189 – ONCO‐THAI – Image Assisted Laser Therapy for Oncology F‐59000 LilleFrance
- Department of Dermatology CHU Lille F‐59000 LilleFrance
| | - P. Deleporte
- Univ. Lille INSERM, CHU Lille, U1189 – ONCO‐THAI – Image Assisted Laser Therapy for Oncology F‐59000 LilleFrance
| | - H. Béhal
- Univ. Lille CHU Lille EA 2694 – Santé Publique: épidémiologie et qualité des soins, Unité de Biostatistiques F‐59000 LilleFrance
| | - D. Kerob
- Galderma International SAS F‐92927 La Défense France
| | - A. Duhamel
- Univ. Lille CHU Lille EA 2694 – Santé Publique: épidémiologie et qualité des soins, Unité de Biostatistiques F‐59000 LilleFrance
| | - S. Mordon
- Univ. Lille INSERM, CHU Lille, U1189 – ONCO‐THAI – Image Assisted Laser Therapy for Oncology F‐59000 LilleFrance
| | - L. Mortier
- Univ. Lille INSERM, CHU Lille, U1189 – ONCO‐THAI – Image Assisted Laser Therapy for Oncology F‐59000 LilleFrance
- Department of Dermatology CHU Lille F‐59000 LilleFrance
| |
Collapse
|
39
|
Karppinen T, Kantola E, Karppinen A, Rantamäki A, Kautiainen H, Mordon S, Guina M. Treatment of telangiectasia on the cheeks with a compact yellow (585 nm) semiconductor laser and a green (532 nm) KTP laser: a randomized double-blinded split-face trial. Lasers Surg Med 2019; 51:223-229. [PMID: 30614016 DOI: 10.1002/lsm.23051] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/07/2018] [Indexed: 01/07/2023]
Abstract
OBJECTIVES The primary objective of this study was to compare a traditional green KTP laser to a new investigational yellow laser (PhotoLase) in the treatment of facial telangiectasia in terms of the treatment outcomes. The secondary objective was to assess the functionality and reliability of the PhotoLase system from the perspective of the user. STUDY DESIGN/METHODS The study was a randomized split-face double-blinded study that compared the treatment efficacy of the 532-nm KTP laser and the investigational 585-nm PhotoLase laser. One or two treatments were given based on the response of the first treatment. The improvement of telangiectasia was graded according to a 7-point Telangiectasia Grading Scale (TGS) by the subjects and blinded physicians. The subjects assessed the amount of pain during the treatments using Visual Analogue Scale (VAS), and evaluated adverse effects 2-3 days after the treatment(s) using a self-assessment form. RESULTS At least 50% improvement was seen in 15/18 subjects after the first PhotoLase treatment, and a similar result was observed for KTP, as assessed by the blinded physicians (P = 0.29). In the subjects' assessment, 7/18 subjects had at least 50% improvement after the first PhotoLase treatment, whereas at least 50% improvement was observed for 10/18 subjects in the KTP side, the difference being significant (P = 0.008). The amount of pain was higher with PhotoLase compared to KTP (67.7 vs. 34.6, P < 0.001). There was no difference in the frequency of erythema, crusting or purpura between the devices, but more blistering and less edema were seen after PhotoLase treatment (P < 0.05). Treatment with PhotoLase was evaluated to be 4.7-fold faster than with KTP and the PhotoLase system was more compact, narrower, lighter, and easier to carry than KTP. CONCLUSIONS The investigational PhotoLase laser enables significantly faster treatments, but the process is somewhat more painful than with KTP, otherwise providing a similar clinical outcome in the treatment of facial telangiectasia. Treatment Protocol Lasers Surg. Med. 51:223-229, 2019. © Wiley Periodicals, Inc.
Collapse
Affiliation(s)
- Toni Karppinen
- Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland.,Department of Dermatology, Tampere University Hospital, Tampere, Finland.,Epilaser Oy, Lempäälä, Finland
| | - Emmi Kantola
- Optoelectronics Research Centre, Tampere University of Technology (TUT), Korkeakoulunkatu 3, 33720, Tampere, Finland
| | | | - Antti Rantamäki
- Optoelectronics Research Centre, Tampere University of Technology (TUT), Korkeakoulunkatu 3, 33720, Tampere, Finland
| | - Hannu Kautiainen
- Unit of Primary Health Care, Helsinki University Central Hospital, Helsinki, Finland.,Department of General Practice, University of Helsinki, Helsinki, Finland.,Unit of Primary Health Care, Kuopio University Hospital, Kuopio, Finland
| | - Serge Mordon
- The French National Institute of Health and Medical Research (INSERM), INSERM U1189-ONCO-THAI, avenue Oscar Lambert 1, 59037, Lille Cedex, France
| | - Mircea Guina
- Optoelectronics Research Centre, Tampere University of Technology (TUT), Korkeakoulunkatu 3, 33720, Tampere, Finland
| |
Collapse
|
40
|
Affiliation(s)
- Clément Dupont
- Université de Lille, Inserm, CHU de Lille, U1189 - ONCO-THAI - Thérapies laser assistées par l'image pour l'oncologie, 59000 Lille, France
| | - Maximilien Vermandel
- Université de Lille, Inserm, CHU de Lille, U1189 - ONCO-THAI - Thérapies laser assistées par l'image pour l'oncologie, 59000 Lille, France - Service de neurochirurgie, CHU de Lille, 59000 Lille, France
| | - Nicolas Reyns
- Université de Lille, Inserm, CHU de Lille, U1189 - ONCO-THAI - Thérapies laser assistées par l'image pour l'oncologie, 59000 Lille, France - Service de neurochirurgie, CHU de Lille, 59000 Lille, France
| | - Serge Mordon
- Université de Lille, Inserm, CHU de Lille, U1189 - ONCO-THAI - Thérapies laser assistées par l'image pour l'oncologie, 59000 Lille, France
| |
Collapse
|
41
|
Vermandel M, Quidet M, Vignion-Dewalle AS, Leroy HA, Leroux B, Mordon S, Reyns N. Comparison of different treatment schemes in 5-ALA interstitial photodynamic therapy for high-grade glioma in a preclinical model: An MRI study. Photodiagnosis Photodyn Ther 2018; 25:166-176. [PMID: 30543907 DOI: 10.1016/j.pdpdt.2018.12.003] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2018] [Revised: 11/14/2018] [Accepted: 12/07/2018] [Indexed: 12/29/2022]
Abstract
BACKGROUND There is currently no therapy that prevents high-grade glioma recurrence. Thus, these primary brain tumors have unfavorable outcomes. Recently, 5-ALA photodynamic therapy (PDT) has been proposed to delay relapse and is highly expected to have potential synergistic effects with the current standard of care. However, PDT treatment delivery needs to be optimized by evaluating the impact of both the number of fractions and the light power used. OBJECTIVES Previous studies have reported MRI examination-based outcomes for PDT in glioblastoma. Our study aimed to compare MRI markers across different treatment schemes that use interstitial PDT in high-grade glioma in a preclinical model. MATERIALS AND METHODS Forty-eight "nude" rats were grafted with human U87 cells into the right putamen and subsequently submitted to interstitial PDT. The rats were randomized into six groups, including two different sham groups and four different treated groups (5 fractions at 5 mW or 30 mW and 2 fractions at 5 mW or 30 mW). After photosensitizer (PS) precursor (5-ALA) intake, an optical fiber was introduced into the tumor. Treatment effects were assessed with early high-field MRI to acquire T1 and T2 diffusion and perfusion images. RESULTS There was no difference in the variation of the diffusion coefficient among the six groups (p = 0.0549, Kruskal-Wallis test). However, a significant difference was identified among the six groups in terms of variation in perfusion (p = 0.048, Kruskal-Wallis test), supporting a lesional effect in the treated groups. Additionally, the sham groups had significantly smaller edema volumes than were observed in the treated groups. Moreover, the 5-fraction group treated with 30 mW was associated with edema volumes that were significantly greater than those in the 5-fraction group treated with 5 mW (p = 0.019). CONCLUSION Based on observations of MRI data and considering treatment effects, the 5-fraction group treated at 5 mW was not significantly different from the other treated groups in terms of cell deaths, characterized by diffusion imaging, or necrosis level. However, the significantly lower level of edema observed in this group indicated that this treatment scheme had limited toxicity.
Collapse
Affiliation(s)
- Maximilien Vermandel
- Univ. Lille, INSERM, CHU Lille, U1189 - ONCO-THAI - Image-Assisted Laser Therapy for Oncology, F-59000, Lille, France; Department of Neurosurgery, University Hospital, F-59000, Lille, France.
| | - Mathilde Quidet
- Department of Neurosurgery, University Hospital, F-59000, Lille, France
| | - Anne-Sophie Vignion-Dewalle
- Univ. Lille, INSERM, CHU Lille, U1189 - ONCO-THAI - Image-Assisted Laser Therapy for Oncology, F-59000, Lille, France
| | - Henri-Arthur Leroy
- Univ. Lille, INSERM, CHU Lille, U1189 - ONCO-THAI - Image-Assisted Laser Therapy for Oncology, F-59000, Lille, France; Department of Neurosurgery, University Hospital, F-59000, Lille, France
| | - Bertrand Leroux
- Univ. Lille, INSERM, CHU Lille, U1189 - ONCO-THAI - Image-Assisted Laser Therapy for Oncology, F-59000, Lille, France
| | - Serge Mordon
- Univ. Lille, INSERM, CHU Lille, U1189 - ONCO-THAI - Image-Assisted Laser Therapy for Oncology, F-59000, Lille, France
| | - Nicolas Reyns
- Univ. Lille, INSERM, CHU Lille, U1189 - ONCO-THAI - Image-Assisted Laser Therapy for Oncology, F-59000, Lille, France; Department of Neurosurgery, University Hospital, F-59000, Lille, France
| |
Collapse
|
42
|
Le Calvé C, Mortier L, Vicentini C, Delaporte E, Maire C, Thecua E, Lecomte F, Rached HA, Mordon S, Deleporte P, Vignon AS. Traitement de la folliculite décalvante par PDT avec dispositifs lumineux textiles : à propos de 2 observations. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.264] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
43
|
Abstract
Hidradenitis suppurativa is a chronic, recurring, and disabling inflammatory condition of the skin. There is no cure for hidradenitis suppurativa and treatment must be adapted to each individual patient. Several studies have been published since 2004 on the use of photodynamic therapy to treat hidradenitis suppurativa. The use of superficial or interstitial illumination with 5-amino-levulinic acid (5-ALA) or methylene blue (MB) have been proposed. Injecting 5-ALA or MB followed by illumination with a fiber optic sensor placed inside the lesion appears to be a better method of treating these thick lesions.
Collapse
Affiliation(s)
- Serge Mordon
- a INSERM, Univ. Lille, CHU Lille, U1189-ONCO-THAI-Image Assisted Laser Therapy for Oncology , Lille , France
| |
Collapse
|
44
|
Mordon S. New optical sources for interstitial and metronomic photodynamic therapy. Photodiagnosis Photodyn Ther 2018; 23:209-211. [PMID: 29981381 DOI: 10.1016/j.pdpdt.2018.07.002] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2018] [Revised: 07/01/2018] [Accepted: 07/02/2018] [Indexed: 01/20/2023]
Abstract
Multiple clinical studies have shown that interstitial photodynamic therapy (iPDT) is a promising modality in the treatment of several cancers. Laser fibers are usually inserted into the target tissue via needles, or placed in catheters. However, they must be removed from the body soon after use. Innovative implantable and biodegradable light sources could offer interesting alternatives since they not need to be removed as they are gradually resorbed by the tissue. Bioabsorbable polymer optical waveguide are relatively easy to manufacture and can deliver substantial light intensities. Near-infrared rechargeable "optical battery" can be easily optimized in size and shape aiming at different nidus sites. Further studies should evaluate the safety of the biodegradation process which will be required in order to approve these light sources on humans.
Collapse
Affiliation(s)
- Serge Mordon
- INSERM, Univ. Lille, CHU Lille, U1189-ONCO-THAI-Image Assisted Laser Therapy for Oncology, Lille, F-59000, France.
| |
Collapse
|
45
|
Vignion-Dewalle AS, Baert G, Thecua E, Lecomte F, Vicentini C, Abi-Rached H, Mortier L, Mordon S. Comparison of 10 efficient protocols for photodynamic therapy of actinic keratosis: How relevant are effective light dose and local damage in predicting the complete response rate at 3 months? Lasers Surg Med 2018; 50:576-589. [PMID: 29667728 DOI: 10.1002/lsm.22827] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/28/2018] [Indexed: 11/07/2022]
Abstract
BACKGROUND Topical photodynamic therapy is an established treatment modality for various dermatological conditions, including actinic keratosis. In Europe, the approved protocols for photodynamic therapy of actinic keratosis involve irradiation with either an Aktilite CL 128 lamp or daylight, whereas irradiation with the Blu-U illuminator is approved in the United States. Many other protocols using irradiation by a variety of light sources are also clinically efficient. OBJECTIVES This paper aims to compare 10 different protocols with clinically proven efficacy for photodynamic therapy of actinic keratosis and the available spectral irradiance of the light source. Effective irradiance, effective light dose, and local damage are compared. We also investigate whether there is an association between the complete response rate at 3 months and the effective light dose or local damage. METHODS The effective irradiance, also referred to as protoporphyrin IX-weighted irradiance, is obtained by integrating the spectral irradiance weighted by the normalized absorption spectrum of protoporphyrin IX over the wavelength. Integrating the effective irradiance over the irradiation time yields the effective light dose, which is also known as the protoporphyrin IX-weighted light dose. Local damage, defined as the total cumulative singlet oxygen molecules produced during treatment, is estimated using mathematical modeling of the photodynamic therapy process. This modeling is based on an iterative procedure taking into account the spatial and temporal variations in the protoporphyrin IX absorption spectrum during treatment. RESULTS The protocol for daylight photodynamic therapy on a clear sunny day, the protocol for daylight photodynamic therapy on an overcast day, the photodynamic therapy protocol for a white LED lamp for operating rooms and the photodynamic therapy protocol for the Blu-U illuminator perform better than the six other protocols-all involving red light illumination-in terms of both effective light dose and local damage. However, no association between the complete response rate at 3 months and the effective light dose or local damage was found. CONCLUSIONS Protocols that achieve high complete response rates at 3 months and low pain scores should be preferred regardless of the effective light dose and local damage. Lasers Surg. Med. 50:576-589, 2018. © 2018 Wiley Periodicals, Inc.
Collapse
Affiliation(s)
- Anne-Sophie Vignion-Dewalle
- Univ. Lille, INSERM, CHU Lille, U1189-ONCO-THAI-Image Assisted Laser Therapy for Oncology, Lille, F-59000, France
| | - Gregory Baert
- Univ. Lille, INSERM, CHU Lille, U1189-ONCO-THAI-Image Assisted Laser Therapy for Oncology, Lille, F-59000, France
| | - Elise Thecua
- Univ. Lille, INSERM, CHU Lille, U1189-ONCO-THAI-Image Assisted Laser Therapy for Oncology, Lille, F-59000, France
| | - Fabienne Lecomte
- Univ. Lille, INSERM, CHU Lille, U1189-ONCO-THAI-Image Assisted Laser Therapy for Oncology, Lille, F-59000, France
| | - Claire Vicentini
- Univ. Lille, INSERM, CHU Lille, U1189-ONCO-THAI-Image Assisted Laser Therapy for Oncology, Lille, F-59000, France.,Department of Dermatology, CHU Lille, Lille, F-5900, France
| | - Henry Abi-Rached
- Univ. Lille, INSERM, CHU Lille, U1189-ONCO-THAI-Image Assisted Laser Therapy for Oncology, Lille, F-59000, France.,Department of Dermatology, CHU Lille, Lille, F-5900, France
| | - Laurent Mortier
- Univ. Lille, INSERM, CHU Lille, U1189-ONCO-THAI-Image Assisted Laser Therapy for Oncology, Lille, F-59000, France.,Department of Dermatology, CHU Lille, Lille, F-5900, France
| | - Serge Mordon
- Univ. Lille, INSERM, CHU Lille, U1189-ONCO-THAI-Image Assisted Laser Therapy for Oncology, Lille, F-59000, France
| |
Collapse
|
46
|
Kerbage Y, Canlorbe G, Estevez JP, Grabarz A, Mordon S, Uzan C, Collinet P, Azaïs H. [Microscopic peritoneal metastases of epithelial ovarian cancers. Clinical relevance, diagnostic and therapeutic tools]. ACTA ACUST UNITED AC 2018; 46:497-502. [PMID: 29656069 DOI: 10.1016/j.gofs.2018.03.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2017] [Indexed: 10/17/2022]
Abstract
Understanding the biology and progression mechanisms of peritoneal metastases in ovarian epithelial cancers (EOC) is important because peritoneal carcinomatosis is present or will occur during surveillance of a majority of patients. Despite the clinical remission achieved after complete macroscopic cytoreductive surgery and platinum-based chemotherapy, 60% of patients will develop peritoneal recurrence. This suggests that microscopic lesions, which are not eradicated by surgery may be present and may participate in the mechanisms leading to peritoneal recurrence. This paper discusses current available data on microscopic peritoneal metastases, their diagnosis and their treatment. We reviewed all publications dealing with microscopic peritoneal metastases of EOC between 1980 and 2017. The most recent and most relevant publications dealing with the treatment modalities of these metastases were selected. Peritoneal and epiploic microscopic localizations would occur in 1.2 to 15.1% of cases at early-stage and are not treated during conventional surgery. They could represent a potential therapeutic target. Local treatments (intraperitoneal chemotherapy, photodynamic therapy, fluorescence-guided surgery) seem to be necessary in addition to surgery and chemotherapy and may help reduce the risk of peritoneal recurrence. The place of these treatments in the management of EOC remains to be defined by subsequent researches.
Collapse
Affiliation(s)
- Y Kerbage
- Service de chirurgie gynécologique, CHU de Lille, 59000 Lille, France; Inserm, U1189, ONCO-THAI, thérapies laser assistées par l'imagerie, 59000 Lille, France
| | - G Canlorbe
- Service de chirurgie et oncologie gynécologique et mammaire, hôpitaux universitaires Pitié-Salpêtrière-Charles-Foix, Pitié-Salpêtrière, AP-HP, 47/83, boulevard de l'Hôpital, 75013 Paris, France
| | - J P Estevez
- Service de chirurgie gynécologique, CHU de Lille, 59000 Lille, France
| | - A Grabarz
- Service de chirurgie gynécologique, CHU de Lille, 59000 Lille, France; Inserm, U1189, ONCO-THAI, thérapies laser assistées par l'imagerie, 59000 Lille, France
| | - S Mordon
- Inserm, U1189, ONCO-THAI, thérapies laser assistées par l'imagerie, 59000 Lille, France
| | - C Uzan
- Service de chirurgie et oncologie gynécologique et mammaire, hôpitaux universitaires Pitié-Salpêtrière-Charles-Foix, Pitié-Salpêtrière, AP-HP, 47/83, boulevard de l'Hôpital, 75013 Paris, France
| | - P Collinet
- Service de chirurgie gynécologique, CHU de Lille, 59000 Lille, France; Inserm, U1189, ONCO-THAI, thérapies laser assistées par l'imagerie, 59000 Lille, France
| | - H Azaïs
- Inserm, U1189, ONCO-THAI, thérapies laser assistées par l'imagerie, 59000 Lille, France; Service de chirurgie et oncologie gynécologique et mammaire, hôpitaux universitaires Pitié-Salpêtrière-Charles-Foix, Pitié-Salpêtrière, AP-HP, 47/83, boulevard de l'Hôpital, 75013 Paris, France.
| |
Collapse
|
47
|
Abstract
For many years, prostate segmentation on MR images concerned only the extraction of the entire gland. Currently, in the focal treatment era, there is a continuously increasing need for the separation of the different parts of the organ. In this paper, we propose an automatic segmentation method based on the use of T2W images and atlas images to segment the prostate and to isolate the peripheral and transition zones. The algorithm consists of two stages. First, the target image is registered with each zonal atlas image then the segmentation is obtained by the application of an evidential C-Means clustering. The method was evaluated on a representative and multi-centric image base and yielded mean Dice accuracy values of 0.81, 0.70, and 0.62 for the prostate, the transition zone, and peripheral zone, respectively.
Collapse
Affiliation(s)
- O Chilali
- INSERM, U1189 - ONCO-THAI - Image Assisted Laser Therapy for Oncology, University of Lille, 59000, Lille, France
- Automatic Department, Mouloud Mammeri University, Tizi-Ouzou, Algeria
| | - P Puech
- INSERM, U1189 - ONCO-THAI - Image Assisted Laser Therapy for Oncology, University of Lille, 59000, Lille, France
- CHRU Lille, Radiology Department, Claude Huriez Hospital, 59000, Lille, France
| | - S Lakroum
- INSERM, U1189 - ONCO-THAI - Image Assisted Laser Therapy for Oncology, University of Lille, 59000, Lille, France
| | - M Diaf
- Automatic Department, Mouloud Mammeri University, Tizi-Ouzou, Algeria
| | - S Mordon
- INSERM, U1189 - ONCO-THAI - Image Assisted Laser Therapy for Oncology, University of Lille, 59000, Lille, France
| | - N Betrouni
- INSERM, U1189 - ONCO-THAI - Image Assisted Laser Therapy for Oncology, University of Lille, 59000, Lille, France.
| |
Collapse
|
48
|
Mordon S, Vignion-Dewalle AS, Thecua E, Vicentini C, Maire C, Deleporte P, Baert G, Lecomte F, Mortier L. Can daylight-PDT be performed indoor? GIORN ITAL DERMAT V 2018; 153:811-816. [PMID: 29417802 DOI: 10.23736/s0392-0488.18.05907-2] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Natural DayLight-mediated PhotoDynamic Therapy (NDL-PDT) is an efficacious treatment option for thin actinic keratosis that offers advantages over conventional PDT in terms of tolerability and cost. It is now accepted that the minimum criteria required for effective NDL-PDT is a dose of 4 J/cm² with a treatment time of 2 hours and a minimum temperature of 10 °C, corresponding to a minimum illuminance of 11,000 lux. This value is easily achievable: 20,000 lux can be obtained during a typical overcast day at midday. It can reach 110,000 lux with a bright sunlight. However, it is limited to certain times of the year at our latitude. However rain and cold temperatures appear the main limitations of NDL-PDT. Greenhouses make possible to perform the illumination even in harsh weather conditions. Furthermore, it is difficult to install a greenhouse everywhere. Several solutions are now proposed to carry out indoor illumination so-called artificial white light or simulated daylight (SDL-PDT). Illumination sources installed at the ceiling of the treatment room is one option. Several lamp pairs can be combined to illuminate groups of patients simultaneously. A surgical theatre light can be used or dedicated systems using white LEDs can be used to deliver the required illumination dose. In conclusion, Indoor lightning (or simulated daylight: SDL-PDT or Artificial White Light: AWL) could offer an interesting alternative to NDL-PDT.
Collapse
Affiliation(s)
- Serge Mordon
- Inserm, CHU Lille, U1189 - ONCO-THAI - Image Assisted Laser Therapy for Oncology, Lille University, Lille, France - serge.mordon @inserm.fr
| | - Anne S Vignion-Dewalle
- Inserm, CHU Lille, U1189 - ONCO-THAI - Image Assisted Laser Therapy for Oncology, Lille University, Lille, France
| | - Elise Thecua
- Inserm, CHU Lille, U1189 - ONCO-THAI - Image Assisted Laser Therapy for Oncology, Lille University, Lille, France
| | - Claire Vicentini
- Inserm, CHU Lille, U1189 - ONCO-THAI - Image Assisted Laser Therapy for Oncology, Lille University, Lille, France.,Department of Dermatology, CHU Lille, Lille, France
| | - Cyril Maire
- Inserm, CHU Lille, U1189 - ONCO-THAI - Image Assisted Laser Therapy for Oncology, Lille University, Lille, France.,Department of Dermatology, CHU Lille, Lille, France
| | - Pascal Deleporte
- Inserm, CHU Lille, U1189 - ONCO-THAI - Image Assisted Laser Therapy for Oncology, Lille University, Lille, France
| | - Gregory Baert
- Inserm, CHU Lille, U1189 - ONCO-THAI - Image Assisted Laser Therapy for Oncology, Lille University, Lille, France
| | - Fabienne Lecomte
- Inserm, CHU Lille, U1189 - ONCO-THAI - Image Assisted Laser Therapy for Oncology, Lille University, Lille, France
| | - Laurent Mortier
- Inserm, CHU Lille, U1189 - ONCO-THAI - Image Assisted Laser Therapy for Oncology, Lille University, Lille, France.,Department of Dermatology, CHU Lille, Lille, France
| |
Collapse
|
49
|
Abstract
Image-guided surgery is a relevant way to reduce surgical morbidity and maximize cytoreductive surgery approach especially in ovarian cancer. Sentinel lymph node detection is a promising approach to avoid radical lymph node dissection and is slightly becoming standard in daily practice in endometrial and cervical cancer surgery even if it needs to be evaluated more precisely. Regarding carcinomatosis of ovarian origin, detection and treatment of microscopic disease could be appropriate to avoid local recurrences. Photodiagnosis and photodynamic therapy are innovative techniques that allow to precise limits of excision (fluorescence-guided surgery) and to treat microscopic disease. Further developments of those strategies are necessary to become standard diagnosis tools and treatment options.
Collapse
Affiliation(s)
- Henri Azaïs
- Department of Gynecological & Breast Surgery & Oncology, AP-HP, Pitié-Salpêtrière, 83 Boulevard de l'Hôpital, 75013 Paris, France; Pierre et Marie Curie University, Paris 6, France.,INSERM, U1189 - ONCO-THAI - Image Assisted Laser Therapy for Oncology, F-59000 Lille, France
| | - Geoffroy Canlorbe
- Department of Gynecological & Breast Surgery & Oncology, AP-HP, Pitié-Salpêtrière, 83 Boulevard de l'Hôpital, 75013 Paris, France; Pierre et Marie Curie University, Paris 6, France
| | - Yohan Kerbage
- INSERM, U1189 - ONCO-THAI - Image Assisted Laser Therapy for Oncology, F-59000 Lille, France.,Department of Gynecologic Surgery, CHU Lille, F-59000 Lille, France
| | - Anne Grabarz
- INSERM, U1189 - ONCO-THAI - Image Assisted Laser Therapy for Oncology, F-59000 Lille, France.,Department of Gynecologic Surgery, CHU Lille, F-59000 Lille, France
| | - Pierre Collinet
- INSERM, U1189 - ONCO-THAI - Image Assisted Laser Therapy for Oncology, F-59000 Lille, France.,Department of Gynecologic Surgery, CHU Lille, F-59000 Lille, France
| | - Serge Mordon
- INSERM, U1189 - ONCO-THAI - Image Assisted Laser Therapy for Oncology, F-59000 Lille, France
| |
Collapse
|
50
|
Leroy HA, Vermandel M, Leroux B, Duhamel A, Lejeune JP, Mordon S, Reyns N. MRI assessment of treatment delivery for interstitial photodynamic therapy of high-grade glioma in a preclinical model. Lasers Surg Med 2017; 50:460-468. [PMID: 29023876 DOI: 10.1002/lsm.22744] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/13/2017] [Indexed: 11/06/2022]
Abstract
BACKGROUND High-grade gliomas are primary brain tumors that have shown increasing incidence and unfavorable outcomes. Local control is crucial to the management of this pathology. Photodynamic therapy (PDT), based on the light-induced activation of a photosensitizer (PS), achieves local treatment by inducing selective lesions in tumor tissue. OBJECTIVES Previous studies have reported the outcomes of PDT for glioblastoma via immunohistological data. Our study aimed to evaluate MRI findings, including diffusion, and perfusion sequences, compared with immunohistological data from the same population to address the efficiency of light fractionation. MATERIALS AND METHODS Twenty-six "nude" rats grafted with human U87 cells into the right putamen underwent PDT. After PS precursor (5-ALA) intake, an optical fiber was introduced into the tumor. The rats were randomized into the following groups: those without illumination and those that received two or five fractions of light. Treatment effects were assessed with early high-field MRI to measure the volume of necrosis and edema using diffusion and perfusion sequences; the MRI results were compared with immunohistology results, including necrosis and apoptosis markers. RESULTS Elevated diffusion values were observed on MRI in the centers of the tumors of the treated animals, especially in the 5-fraction group (P < 0.01). Perfusion was decreased around the treatment site, especially in the 5-fraction group (P = 0.024). The MRI findings were consistent with previously published histological data. The median volume of necrosis was significantly different between the sham group and treated groups, 0 mm3 versus 2.67 mm3 , P < 0.001. The same trend was previously observed in histology data when grading the absence or presence of necrosis and when the presence of necrosis was significantly more predominant for the treated group than for the untreated group (P < 001). Additionally, cell death represented by apoptosis marker data (TUNEL method) was significantly higher in the 5-fraction group than in the 2-fraction group (P = 0.01). CONCLUSION Diffusion and perfusion MRI revealed histological lesions. Interstitial PDT (iPDT) induced specific lesions in the tumor tissue, which were observed with MRI and confirmed by histopathological analysis. Thus, MRI may provide a non-invasive and reliable tool to assess treatment outcomes after PDT. Lasers Surg. Med. 50:460-468, 2018. © 2017 Wiley Periodicals, Inc.
Collapse
Affiliation(s)
- Henri-Arthur Leroy
- Univ. Lille, INSERM, CHU Lille, U1189-ONCO-THAI-Image Assisted Laser Therapy for Oncology, F-59000, Lille, France.,Department of Neurosurgery, University Hospital, Lille, France
| | - Maximilien Vermandel
- Univ. Lille, INSERM, CHU Lille, U1189-ONCO-THAI-Image Assisted Laser Therapy for Oncology, F-59000, Lille, France
| | - Bertrand Leroux
- Univ. Lille, INSERM, CHU Lille, U1189-ONCO-THAI-Image Assisted Laser Therapy for Oncology, F-59000, Lille, France
| | - Alain Duhamel
- Department of Biostatistics, EA2694, UDSL, University of Lille, University Hospital, Lille, France
| | - Jean-Paul Lejeune
- Univ. Lille, INSERM, CHU Lille, U1189-ONCO-THAI-Image Assisted Laser Therapy for Oncology, F-59000, Lille, France.,Department of Neurosurgery, University Hospital, Lille, France
| | - Serge Mordon
- Univ. Lille, INSERM, CHU Lille, U1189-ONCO-THAI-Image Assisted Laser Therapy for Oncology, F-59000, Lille, France
| | - Nicolas Reyns
- Univ. Lille, INSERM, CHU Lille, U1189-ONCO-THAI-Image Assisted Laser Therapy for Oncology, F-59000, Lille, France.,Department of Neurosurgery, University Hospital, Lille, France
| |
Collapse
|